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ABSTRACT
cis-Diamminedichloroplatinum(II) (cis-DDP or cisplatin) is a powerful
cytotoxin and anticancer therapeutic, used most effectively in the treatment of
testicular and ovarian cancers. By contrast, the geometric isomer of cisplatin, trans-
DDP, is comparatively non-toxic and fails to show significant antitumor activity.
Cisplatin is believed to derive its cytotoxic effects from processes triggered by its
reaction with DNA. The formation of cisplatin adducts can elicit many cellular
responses, including inhibition of both DNA replication and transcription. Cisplatin
DNA adducts are also specifically recognized by various proteins within the cell, and
such cisplatin-damage recognition proteins have been previously suggested to play a
role in the clinical efficacy of the drug. To date, however, the precise mechanism by
which cisplatin lesions mediate the cytotoxic and antitumor activities of cisplatin
remains elusive. The work in this dissertation evaluated two possible mechanisms by
which cisplatin might exert its cytotoxic effects that had been heretofore largely
unexplored.
The first aspect of this work evaluated a model wherein the differential
cytotoxic and antitumor activities of cisplatin and trans-DDP may result from a
greater ability of cisplatin DNA damage to inhibit RNA transcription. A
nonreplicating plasmid harboring the 0-galactosidase (f-gal) reporter gene was
modified in vitro with either of the two platinum compounds and transfected into
human or hamster cell lines. The use of cell lines both proficient and deficient in
nucleotide excision repair allowed the examination of transcriptional bypass
independent of excision repair for each platinum compound. A two to three fold
higher level of transcription was observed in both cell lines from plasmids containing
trans-DDP adducts as compared to plasmids modified by cis-DDP. This difference in
transcriptional activity was not decreased in human and rodent nucleotide excision
repair deficient cell lines, indicating that more efficient excision repair of the trans-
DDP adducts was not the cause of its lower ability to block transcription. The
possibility that trans-DDP lesions are preferentially bypassed by RNA polymerase was
examined by monitoring the elongation of 3-gal mRNA on damaged templates in vivo.
Nascent 1-gal mRNA transcripts were recovered from nucleotide excision repair
deficient xeroderma pigmentosum A cells transfected with platinated plasmids, and the
extent of RNA synthesis was measured by using ribonuclease protection. The results
showed that four-fold more trans-DDP than cis-DDP adducts were required to inhibit
transcription elongation by 63 %. RNA polymerase II translocated past a single,
representative DNA adduct of cisplatin and trans-DDP in vivo with an efficiency of 0-
16% and 60-76%, respectively. These data support the view that inhibition of
transcription may contribute to the greater cytotoxicity of cis-DDP compared with its
trans isomer.
The second aspect of this work evaluated a possible novel role of the human
mismatch repair protein, hMSH2, as a cisplatin-damage recognition protein. The
interaction of purified recombinant hMSH2 with DNA containing adducts of cisplatin
and various cisplatin analogs was examined in vitro by using an electrophoretic gel
mobility shift assay. The results showed that hMSH2 recognizes and binds
specifically to DNA adducts of cisplatin. This protein displayed affinity for DNA
modified by therapeutically effective platinum complexes, but not for that modified by
clinically inactive platinum compounds such as trans-DDP. Recognition by hMSH2
was dictated, in part, by the major intrastrand DNA adduct formed by cisplatin. The
results also show that hMSH2 is overexpressed in testicular and ovarian tissue, tissues
in which tumors are best treated by cisplatin. These results complement a growing
body of literature correlating mismatch repair activity with cisplatin toxicity in
Escherichia coli and mammalian cells. Viewed together, these observations are
consistent with a model whereby mismatch repair plays an active role in potentiating
cisplatin DNA lesion toxicity. Further, these results may provide insight into a
previously undiscovered mechanism by which tumor cells may acquire resistance to
cisplatin.
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I. INTRODUCTION
The coordination complex cis-diamminedichloroplatinum(II) (cisplatin or cis-
DDP) was first synthesized in 1845, and is a classic example of compounds having a
square planar structure (Lippard, 1982) (Figure 1). The biological effects of platinum
complexes were discovered serendipitously by Barnett Rosenberg in 1965 during his
experiments examining the effects of electrical fields on bacteria (Rosenberg et al.,
1965). Rosenberg observed that growing Escherichia coli between charged platinum
electrodes resulted in inhibition of cell division, but not cell growth. One of the
agents responsible for this effect was found to be cis-DDP, which had been formed in
the course of the experiments by electrolysis at the electrodes. The marked effects of
cisplatin on bacterial cell division suggested that cisplatin could have potential value
as an anticancer agent. Soon thereafter cisplatin was shown to have significant
antitumor activity against sarcoma 180 and leukemia L1210 in mice (Rosenberg et al.,
1969). Interestingly, the geometric isomer of cisplatin, trans-
diamminedichloroplatinum(II) (trans-DDP) (Figure 1), displayed no antitumor
activity. Since cisplatin received FDA approval in 1979, it has proved remarkably
successful as an anticancer therapeutic.
Testicular cancer has a relatively minor incidence of approximately 4.5 in
100,000 males and represents only a small fraction (- 0.6%) of all new cancer cases in
a given year (Feuer et al., 1993). Over 6,000 men in the United States, generally
between the ages of 20 and 44, are diagnosed with the disease each year. Since
1973, significant improvements in survival rates for testicular cancer have led to an
overall 65 % decline in mortality rate despite a 49% increase in incidence over the
same time period (Feuer et al., 1993). This marked increase in cure rate has been a
direct extension of the successful use of cisplatin-based chemotherapeutic regiments
(Loehrer and Einhorn, 1984). Indeed, before the incorporation of cisplatin into
combined therapies with vinblastine and bleomycin, few patients with advanced
nonseminomatous testicular cancer were expected to survive beyond 1-2 years.
According to recent estimates, testicular cancers are now 96% curable by a
combination of surgery followed by chemotherapy with a regimen involving cisplatin
as the principal cytotoxic agent (Feuer et al., 1993). In addition to its success in
treating testicular cancer, cisplatin also displays significant activity against cancers of
the ovary, cervix, bladder, lung, head and neck.
Few cytotoxic drugs are adequately selective for tumor cells, while sparing
normal tissues, and cisplatin is no exception; treatment-related side effects include
severe gastrointestinal toxicity, renal failure, hearing loss and peripheral nerve
damage (Loehrer and Einhorn, 1984). Some of these effects have been partially
alleviated by pre-hydration of patients with physiological saline and mannitol before
administering cisplatin, as well as through careful dosage control (Loehrer and
Einhorn, 1984). Despite such improvements, the remaining drawbacks to cisplatin
therapy, including the side effects still associated with cisplatin treatment, its limited
effectiveness for a subset of cancers, and acquired drug tumor resistance, underscore
the ongoing need for new and novel anticancer agents. To this end, achieving a full
understanding of the mechanism of action of cisplatin will facilitate the rational design
of more selective compounds that are effective against a broader range of tumor
types.
Although the precise mechanism of action of cisplatin remains unclear, it is
well established that cisplatin's cytotoxic effects derive from processes triggered by its
reaction with DNA (Bruhn et al., 1990). Cisplatin forms a variety of DNA adducts,
most of which induce significant structural distortion such as bending and unwinding
of the DNA helix. Cisplatin DNA adducts are capable of blocking DNA synthesis
(Pinto and Lippard, 1985; Alazard et al., 1982; Salles et al., 1983), and it has been
widely postulated that cisplatin, like many chemotherapeutic agents, exerts its
antitumor effects through the inhibition of DNA synthesis in rapidly dividing cancer
cells. However, DNA damage caused by the therapeutically ineffective isomer of
cisplatin, trans-DDP, has been found to be equally effective as that of cisplatin at
inhibiting DNA replication (Harder et al., 1976; Bernges and Holler, 1988;
Heiger-Bernays et al., 1990; Salles et al., 1983; Ciccarelli et al., 1985). Moreover,
simple inhibition of DNA synthesis cannot explain the organotropic specificity of
cisplatin. These observations suggest that additional mechanisms apart from the
inhibition of DNA replication may also be at work. The goal of this thesis work was
to explore two alternative modes of cytotoxicity for cisplatin. In this work, the
geometric isomer trans-DDP, which lacks antitumor activity, was used as a
comparitor to calibrate the relative importance of specific interactions of cisplatin
DNA adducts with molecules within the cell.
The first goal of this thesis was to evaluate a model wherein the differential
cytotoxic and antitumor activities of cis- and trans-DDP may result from a greater
ability of cis-DDP DNA damage to inhibit RNA transcription. Supporting this
hypothesis are results from a study comparing the effects of cis- and trans-DDP
adducts on RNA polymerase processivity in vitro. DNA adducts formed by cis-DDP
were found to be a complete block to transcription elongation by Escherichia coli or
wheat germ RNA polymerases; by contrast, a major DNA adduct formed by trans-
DDP was effectively bypassed by these RNA polymerases (Corda et al., 1991; Corda
et al., 1993; Brabec and Leng, 1993). A study of the effects of cis- and trans-DDP
on transcription in vivo has demonstrated that cis-DDP can inhibit initiation of
transcription by preventing the binding of a transcription factor to its cognate
promoter; cis-DDP was found to reduce the changes in nucleosomal organization
required for transcription factor access, but trans-DDP did not (Mymryk et al., 1995).
Unfortunately, no direct comparison between the two isomers can be made from this
study because the relative number of platinum DNA adducts formed in cells after
treatment with each platinum isomer was not determined. Prior to this thesis work,
an examination of the inhibition of transcription elongation by platinum DNA adducts
in vivo was distinctly lacking. The results of the first part of this dissertation show
that RNA polymerase II translocates past a single, representative DNA adduct of
trans-DDP with a minimum 5-fold greater efficiency than that of cis-DDP in vivo
(Mello et al., 1995). These results support the view that inhibition of transcription
may contribute to the cytotoxic activity of cisplatin.
The second goal of this thesis work was to evaluate the possible role of the
human mismatch repair protein hMSH2 in the mechanism of action of cisplatin.
Long-patch mismatch repair is a pathway responsible for the correction of mismatched
bases arising as a result of replication errors and recombination events (Modrich,
1991). The rationale for investigating a possible connection between mismatch repair
proteins and cisplatin stems from several independent observations made with respect
to mismatch repair in the literature. One such observation was made in early studies
carried out by Martin Marinus and colleagues investigating mismatch repair in E. coli
(Karran and Marinus, 1982; Fram et al., 1985). In this work dam- strains were
shown to be hypersensitive to the cytotoxic effects of both the methylating agent N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG) and cisplatin. Interestingly, additional
mutations that inactivate mismatch repair activity (mutL, mutS) in these cells were
found to abrogate hypersensitivity to both agents. These results suggested that
mismatch repair plays an active role in sensitizing E. coli cells to the cytotoxic effects
of both MNNG and cisplatin. More recently these observations for MNNG were
extended to higher eukaryotes; mammalian cell lines defective in mismatch repair
were found to exhibit resistance to methylating agents (Kat et al., 1993; Branch et al.,
1993; Branch et al., 1995; Aquilina et al., 1995). Taken together, these observations
suggested that mismatch repair proteins could be involved in the mechanism of
cisplatin toxicity in mammalian cells.
A second rationale for these studies came from the existing knowledge of a
family of cellular proteins that bind specifically to cisplatin DNA adducts (Bruhn et
al., 1992; Toney et al., 1989; Pil and Lippard, 1992; Lieberman et al., 1992). This
protein family shares a common DNA binding motif with the non-histone
chromosomal protein high mobility group 1 (HMG1). HMG-box proteins possess
both sequence- and structure-specific DNA binding properties that include an affinity
for bent DNA structures, such as four-way junction and cruciform DNA (Bianchi et
al., 1992; Ferrari et al., 1992; Lilley, 1992). HMG box protein binding can also
induce a dramatic bend in linear DNA sequences (Ferrari et al., 1992; Giese et al.,
1992; Pil et al., 1993). It is therefore believed that duplex DNA bending and
unwinding induced by cisplatin adducts (Bellon and Lippard, 1990; Bellon et al.,
1991) provide the structural signal for HMG box protein recognition (Donahue et al.,
1990; Bruhn et al., 1992). An intriguing observation made for both Saccharomyces
cerevisiae and human MSH2 was that these proteins, in addition to recognizing single
base mismatches, display an affinity for insertion/deletion mispairs and palindromic
loops containing up to 14 extrahelical bases (Alani et al., 1995; Fishel et al., 1994a).
Such palindromic loops create DNA structures highly reminiscent of cruciform DNA
recognized by HMG proteins. These observations suggested that hMSH2, like HMG-
box proteins, might recognize structural distortions induced by cisplatin DNA
adducts.
Several models have been proposed and tested to explain the possible
involvement of HMG-box proteins in the mechanism of action of cisplatin (see
literature survey). To date, however, these models have failed to explain an
important feature of cisplatin's pharmacological effects, namely its organotropic
specificity for testicular and, to a lesser extent, ovarian tumors. Correlations between
the expression levels of HMG-box proteins and those tissues best treated by cisplatin
have not been described. An interesting observation in the literature, therefore, was
that testicular tissue displays elevated levels of hMSH2 mRNA (Wilson et al., 1995).
This reported overexpression provided a third motivation to explore potential
interactions between cisplatin modified DNA and hMSH2. The work in the second
part of this dissertation demonstrates that hMSH2 binds selectively to the DNA
adducts of platinum based drugs that show clinical efficacy or potential. This work
also shows that hMSH2 is overexpressed in both testis and ovary at the protein level
(Mello et al., 1996). These results are consistent with a role for hMSH2 in the
antitumor activity and organotropism of this important anticancer drug.
Figure 1: Chemical structures of the anticancer drug cisplatin and its therapeutically
ineffective geometric isomer trans-DDP.
CI
Pt
NH3
CI
NH3
cis-DDP
CI NH3
Pt
NH3 CI
trans-DDP
II. LITERATURE SURVEY
The success of cisplatin in the cure of testicular cancer has stimulated much
interest in its biochemical mechanism(s) of action. To date, the precise mechanism
by which cisplatin kills tumor cells remains elusive. Cisplatin can react with various
macromolecules inside the cell, including DNA, RNA and proteins. It is widely
believed, however, that cisplatin kills cells by processes triggered as a result of its
reaction with DNA (Bruhn et al., 1990). Several lines of evidence strongly support
this view. First, an examination of the number of platinum atoms bound to DNA,
RNA and protein molecules in HeLa cells treated with cisplatin at its mean lethal dose
indicates that relatively few protein molecules (one platinum adduct per 3-10,000
protein molecules) and RNA molecules (one platinum adduct per 10-1000 RNA
molecules) are damaged by cisplatin compared to DNA molecules (nine platinum
adducts per molecule) (Akaboshi et al., 1992). A study by Pascoe and Roberts found
similar results (Pascoe and Roberts, 1974). Furthermore, it is reasoned that any of
these damaged protein or RNA molecules, in contrast to that of DNA, are expendable
and easily replaced. It could be argued, however, that some low abundance regulator
of a critical event, such as control of apoptosis, may be a target of cisplatin. It is
worth keeping an open mind to such options, although to date no data support them.
The second line of evidence stems from several studies in which patients with
different types of malignancies undergoing cisplatin therapy were monitored for levels
of cisplatin adducts formed in their peripheral blood leukocytes. From these trials it
was found that high levels of cisplatin adducts in the DNA of these patients correlates
extremely well with a favorable response to cisplatin treatment (Reed et al., 1987;
Reed et al., 1988; Reed et al., 1993). It is difficult to build a strong case on the
basis of such correlative evidence, however, because some non-DNA target not
measured may have shown equal or better correlation.
The most compelling evidence supporting DNA as the target of cisplatin is the
body of evidence showing that mammalian cells with a deficiency in nucleotide
excision repair, which as a consequence accumulate great numbers of cisplatin DNA
adducts, are much more sensitive to the drug than wild type cells (Hoy et al., 1985;
Chu and Berg, 1987; Dijt et al., 1988). This evidence strongly supports the view that
the cytotoxic effects of cisplatin derive primarily from its coordination to DNA.
Significant effort has thus focused on the nature of that DNA damage, as well as how
cells react to and process cisplatin lesions.
A. DNA adducts formed by cis- and trans-DDP
Cisplatin is not very reactive in the bloodstream, where the chloride
concentration is high (- 100 mM). Upon diffusion into a cell, however, the low
concentration of chloride (- 3 mM) facilitates hydrolysis of the two chloride ligands
yielding a positively charged, bifunctional electrophilic derivative. This aquated
species reacts rapidly with DNA primarily at the N7 position of purine bases to form
monofunctional adducts; subsequent reaction with a second nucleophile yields
bifunctional intrastrand and interstrand crosslinks, as well as a small proportion of
DNA-protein crosslinks (Bruhn et al., 1990) (summarized in Figure 2). The half-life
of the monofunctional species in vitro is 4.1 hours, as determined by kinetics studies
using 195Pt-NMR (Bancroft et al., 1990). The primary DNA adducts formed by cis-
DDP upon treatment of DNA in vitro include the intrastrand 1,2-d(GpG), 1,2-
d(ApG), and 1,3-d(GpNpG) crosslinks (where N is any nucleotide) (Figure 3),
representing approximately 65%, 25 % and 8% of the total adducts formed,
respectively (Eastman, 1983; Fichtinger-Schepman et al., 1985). Interstrand
crosslinks are formed between two guanines in opposing strands at d(GpC) / d(GpC)
sites (Eastman, 1985; Zou et al., 1994), although at a much lower frequency of <:2%
(Bruhn et al., 1990). Monofunctional adducts account for less than 1% of the total
adduct profile (Fichtinger-Schepman et al., 1985). The examination of platinum
adducts found in the DNA of mammalian cells grown in culture, or of circulating
leukocytes of patients, following treatment with the drug reveal adduct profiles
extremely similar to that found in vitro (Plooy et al., 1985; Fichtinger-Schepman et
al., 1987).
The trans isomer of cisplatin, trans-DDP, is at least 20-fold less cytotoxic
than cisplatin (Pascoe and Roberts, 1974) and is ineffective against tumors. This
platinum compound also binds, although not exclusively, through the N7 position of
purine bases in DNA, and forms a variety of monofunctional (Eastman and Barry,
1987) and bifunctional adducts (Eastman et al., 1988) (summarized in Figure 1).
Kinetic studies using '95Pt-NMR determined the half-life of the trans-DDP
monofunctional species in vitro to be 5.1 hours (Bancroft et al., 1990). The trans
isomer is stereochemically hindered from forming the 1,2-intrastand crosslinks that
comprise the majority of adducts formed by cis-DDP (Cohen et al., 1980; Pinto and
Lippard, 1985) and instead forms predominantly intrastrand crosslinks at bases
separated by one or more intervening nucleotides (Figure 2). Unfortunately, the
trans-DDP adduct spectrum is not as well characterized as that of cisplatin. Reaction
of trans-DDP with single stranded DNA and subsequent analysis of enzymatic
digestion products reveals bifunctional crosslinks with the connectivities dG-Pt-dG
(60%), dG-Pt-dA (35%) and dG-Pt-dC (5%) (Eastman et al., 1988); consistent with
these findings are the results of replication mapping studies suggesting a preference
for d(GpNpG) sequences (Pinto and Lippard, 1985). Bifunctional adducts formed by
trans-DDP in duplex DNA exhibit a different distribution from that observed in single
stranded DNA: dG-Pt-dC, dG-Pt-dG and dG-Pt-dA represent 50%, 40% and 10% of
the total crosslinks, respectively (Eastman et al., 1988). A distinction between
intrastrand adducts at nonadjacent bases and interstrand crosslinks could not be made
by the methods used in this experiment. However, the preferential formation of dG-
Pt-dC in duplex DNA suggests that it derived, at least in part, from an interstrand
crosslink. More recently, interstrand adducts of trans-DDP have been characterized;
the crosslinks indeed occur at complementary guanine and cytosine bases, and are
estimated to comprise up to 20% of the total adduct profile (Eastman et al., 1988;
Brabec and Leng, 1993).
Leng and colleagues have made the observation that the 1,3-d(GpApG)
crosslink of trans-DDP present in a single stranded oligonucleotide undergoes
isomerization to the interstrand crosslink when the oligonucleotide is paired with its
complementary strand (Dalbies et al., 1994). This finding suggests that 1,3-
intrastrand crosslinks of the trans isomer, at least in some sequence contexts, may be
unstable. Isomerization of the 1,3-d(GpCpG) trans-DDP adduct present in a single
stranded oligonucleotide to a 1,4-d(CpGpCpG) intrastrand adduct has also been
observed (Comess et al., 1990). Interestingly, Leng and colleagues also report
recently that when duplex DNA fragments globally modified with trans-DDP were
examined to detect possible intrastrand crosslinks using the 3' - 5' exonuclease
activity of T4 DNA polymerase, virtually no such crosslinks were detected
(Boudvillain et al., 1995). The level of trans-DDP modification used in this
experiment was extremely low, however, and would very likely have been below the
limits of detection of their experimental system. The adduct profile formed in
genomic DNA following treatment of cells with trans-DDP has not been examined.
Structural distortions induced to DNA by the various platinum adducts
discussed above have been studied by numerous methods including polyacrylamide gel
electrophoresis, chemical probes, nuclear magnetic resonance (NMR) and X-ray
crystallography. Gel electrophoretic mobility studies of DNA fragments containing
site-specific cisplatin adducts have demonstrated that the 1,2-d(GpG), 1,2-d(ApG) and
1,3-d(GpTpG) intrastrand crosslinks each impart a directed bend to the DNA helix of
approximately 340 towards the major groove (Bellon and Lippard, 1990). The 1,2-
d(GpG) and 1,2-d(ApG) adducts also induce local unwinding of the duplex by 130,
while the 1,3-d(GpTpG) crosslink causes unwinding of 230 (Bellon et al., 1991).
Reactivity studies with chemical probes reveal that in the case of the 1,3-d(GpTpG)
crosslink, base pairing at the 5' G and T is disrupted, while the 3' G base pairing is
unperturbed. For both the 1,2-d(ApG) and 1,3-d(GpTpG) crosslinks, the DNA helix
is more distorted at the 5' side of the adduct (Marrot and Leng, 1989; Anin and
Leng, 1990).
Analysis by X-ray crystallography of cisplatin coordinated to the dinucleotide
d(GpG) has shown that the base stacking of the coordinated guanines is disrupted
(Sherman et al., 1985). Very recently, an X-ray structure of the 1,2-d(GpG) adduct
present in a duplex dodecamer has been solved (Takahara et al., 1995). This
structure revealed that the local minor groove width is widened significantly (9.2-11.2
A vs. the normal 5.7 A of normal B-DNA) and, consistent with the earlier
crystallographic study, that the guanine bases are destacked. The conformation of the
deoxyribose at the 5' and 3' G nucleotide is C3'-endo and C2'-endo, respectively.
Most striking was the finding of an abrupt change from B-type DNA to one
resembling an A-type DNA architecture that extends well beyond the platinum lesion;
it is possible that this unique structure was influenced by crystal packing. The
structure of the 1,2-d(GpG) adduct in a 8-bp duplex has also been determined recently
by NMR spectroscopy (Yang et al., 1995). The NMR structure indicates slightly
greater bending (- 58o) and unwinding (210) than was found by gel mobility studies,
confirms that the minor groove is widened at the lesion site, and, in contrast to the
crystal structure, indicates that the 5' G base pair is disrupted. Conformations of the
sugars are consistent with the crystal structure. Interestingly, in this same study it is
reported that the 1,2-d(GpG) intrastrand adduct undergoes slow isomerization to an
interstrand crosslink in the presence of chloride ion. Whether this reaction may be
promoted in vivo by other nucleophilic biological ligands is not known.
Gel electrophoretic mobility studies of the 1,3-d(GpTpG) intrastrand crosslink
of trans-DDP indicate that the lesion imparts a nondirected bend, or point of
flexibility, to the DNA helix resembling a hinge joint (Bellon and Lippard, 1990;
Bellon et al., 1991). This is in contrast to the rigid bend induced by each of the
intrastrand adducts of cisplatin. Unwinding induced in plasmid DNA by global trans-
DDP modification is reported to be - 9' . Interestingly, monofunctional adducts of the
cisplatin analog [Pt(dien)Cl]C1, which has only one labile chloride and thus can
coordinate to only one nucleophile, unwind the helix by - 6' (Keck and Lippard,
1992). In a separate study, global cis-DDP modification was found to be twice as
effective at unwinding supercoiled plasmid DNA as trans-DDP damage (Scovell and
Collart, 1985). Thus trans-DDP intrastrand crosslinks appear to induce less
unwinding and rigid bending than their cisplatin counterparts.
The structural consequences of cis- and trans-DDP interstrand crosslinks to
DNA have also been examined. Both interstrand crosslinks appear to distort the
DNA helix over a larger area than the intrastrand 1,2-d(GpG) cisplatin adduct
(Schwartz and Leng, 1994). Electrophoretic mobility studies and reactivity assays
using several different chemical probes indicate that a trans-DDP interstrand crosslink
at a G/C base pair bends the helix towards the major groove by - 260, unwinds it by -
120, and suggest that the platinum coordinated nucleotides remain base paired (Brabec
et al., 1993). Similar studies examining a cisplatin interstrand crosslink at a
d(GpC)/d(GpC) site reveal a bend angle of 550 and unwinding by 790 (Sip et al.,
1992; Malinge et al., 1994). A structure of this same adduct was recently determined
by NMR, confirming that both cytosine bases are extrahelical, and that a localized
change of helix from right- to left-handed at the site of the lesion results in a net
unwinding of 870 that spans approximately four bases. A very unexpected finding,
however, is that the cisplatin bridge actually lies in the minor groove, and imparts a
200 bend to the helix towards the minor groove (Huang et al., 1995). This minor
groove positioning of the platinum bridge is in complete contrast to that seen for
cisplatin intrastrand adducts and, if accurate, emphasizes the structural differences
between interstrand and intrastrand cisplatin adducts.
The fact that trans-DDP cannot form 1,2-intrastrand crosslinks, which
comprise greater than 90% of all adducts formed by cis-DDP, has led to the proposal
that the 1,2-intrastrand adducts are responsible for the therapeutic activity of cisplatin.
Recent findings that cellular proteins that recognize damaged DNA architectural
features that correlate with therapeutic efficacy bind specifically to these 1,2-
intrastrand crosslinks lends support to this view. By similar reasoning, cis-DDP
interstrand crosslinks are not thought to be responsible for the mechanism of cisplatin
toxicity owing to the fact that the trans isomer forms significantly greater levels of
this type of adduct. Such arguments rely on the assumption that cis- and trans-DDP
interstrand crosslinks and/or 1,3-intrastrand crosslinks are structurally similar, while
the discussion above clearly illustrates that this is not the case. Thus, until a
mechanism of action is fully elucidated, all cisplatin adducts formally remain potential
candidates for the specific lesion(s) that mediates the cytotoxic and therapeutic
activities of the drug.
B. Cellular responses to cisplatin
1. Effects on DNA replication
Although the precise biochemical mechanism by which cis-DDP selectively
kills cancer cells is not fully known, the DNA adducts of this platinum compound
block both replication and transcription. It has been postulated, and it is indeed a
widely held belief, that inhibition of DNA replication represents the primary
mechanism by which cisplatin exerts its antitumor effects. Replication inhibition by
cisplatin lesions is thought to slow or block cell division, therein providing a trigger
for cell death. According to this hypothesis cisplatin would, importantly, have more
pronounced effects on rapidly dividing cells, such as tumor cells. Extensive efforts
have thus focused on studying the effects of cisplatin and its trans isomer on DNA
replication both in vitro and in vivo.
Globally modified single-stranded DNA templates have been used in studies
examining the ability of E. coli DNA polymerase I to carry out second strand
synthesis on platinated templates in vitro. cis-DDP adducts were found to block DNA
polymerase I efficiently, and at sequences consistent with known sites of adduction
(Pinto and Lippard, 1985; Villani et al., 1988). trans-DDP adducts also blocked well
(Pinto and Lippard, 1985), while monofunctional adducts of cisplatin or the cisplatin
analog [Pt(dien)Cl]Cl did not block the polymerase (Pinto and Lippard, 1985;
Hoffmann et al., 1989). Strong inhibition by cisplatin modification has also been
observed with eukaryotic enzymes. cis-DDP bifunctional adducts, but not
monofunctional adducts, blocked purified calf thymus DNA polymerase a efficiently,
and at numerous sites along the template that again correlated with preferential sites
of adduct formation (Villani et al., 1988; Hoffmann et al., 1989). Using partially
purified calf thymus DNA polymerase a and polymerase 3, the modification level of
cis- and trans-DDP that reduced template activity by 50% was found to differ by - 1.5,
indicating that the two compounds inhibit DNA synthesis similarly (Harder et al.,
1976). The two platinum isomers were also compared using an SV40-based in vitro
replication system in which DNA synthesis was carried out by DNA polymerases
present in HeLa or human embryonic kidney 293 cell-free extracts; in this system
additional cellular factors that might aid polymerases in translocating past DNA
damage would presumably be present. cis- and trans-DDP adducts present on double
stranded plasmid templates at an rb = 9 x 10-4 both inhibited replication by 95 %,
while the same level of [Pt(dien)Cl]Cl monofunctional adducts produced 20%
inhibition (Heiger-Bernays et al., 1990). These studies suggest that the two platinum
isomers are equally effective at inhibiting DNA polymerases in vitro.
The studies described above using globally modified DNA indicate that several
different platinum adducts block DNA replication. Site-specifically modified DNAs
have been useful in assessing the relative abilities of individual platinum lesions to
inhibit DNA polymerases in vitro. Comess and colleagues examined primer
elongation on site-specifically platinated templates by the four enzymes E. coli DNA
polymerase I, E. coli DNA polymerase III holoenzyme, bacteriophage T7 polymerase
and T4 polymerase (Comess et al., 1992). Translesion synthesis was observed for
each platinum adduct examined. Cisplatin intrastrand adducts inhibited DNA
polymerases with the relative efficiencies: 1,2-d(GpG) > 1,2-d(ApG) > 1,3-
d(GpCpG), with an average bypass efficiency of - 10%. The trans-DDP 1,4-
d(CpGpCpG) crosslink was found to be a poor block to DNA synthesis. Although
this differential inhibition by cis- and trans-DDP appears at odds with results from
studies using globally modified templates, it is important to note that a 1,4-
d(CpGpCpG) crosslink is not likely representative of the adducts formed by trans-
DDP.
Site-specifically platinated DNA templates have also been employed in studies
with eukaryotic enzymes. Purified calf thymus DNA polymerase e is completely
inhibited by a cisplatin 1,2-d(GpG) crosslink, as is the 3' - 5' proofreading
exonuclease activity of the polymerase (Huang et al., 1993). Progression of DNA
polymerase E was also blocked by monofunctional cisplatin adducts on guanines. A
more recent study has compared the effect of a 1,2-d(GpG) cisplatin crosslink, which
was positioned on codon 13 within the human protooncogene HRAS sequence, on four
of the five known eukaryotic DNA polymerases. In an earlier study, the 1,2-d(GpG)
crosslink positioned in this same sequence in an SV40 based shuttle vector was
efficiently replicated in monkey COS-7 cells, leading to mutations at the lesion site
(Pillaire et al., 1994). Results revealed that DNA polymerases 01, -y and e are
completely blocked at the site of the lesion, whereas DNA polymerase 0 is able to
bypass the adduct efficiently (Hoffmann et al., 1995). Moreover, DNA polymerase 3
is able to initiate elongation directly opposite the lesion and to compete at the
replication fork with the other enzymes when stalled at the lesion. Interestingly, the
crystal structure of DNA polymerase 0 shows structural similarity to E. coli DNA
polymerase I (Pelletier et al., 1994; Sawaya et al., 1994), which also bypasses the
1,2-d(GpG) adduct (vide supra).
The ability of platinum adducts to inhibit DNA synthesis has also been
examined extensively in vivo. Treatment of mouse lymphoma cells grown in culture
with cis- or trans-DDP revealed equal inhibition of DNA replication by the two
compounds when serum is absent from the media. It is noteworthy that in the
presence of serum, sulfur-containing molecules selectively sequester trans-DDP in the
medium, thereby significantly reducing DNA synthesis inhibition by this compound
(Uchida et al., 1986). In a separate study, treatment of a L1210 leukemia cell line
with platinum compounds shows that 50% inhibition of DNA synthesis was achieved
when 1.8 x 10 -4 , 2.4 x 10-4 and 80 x 10-4 platinum atoms are bound/nucleotide for
cis-DDP, trans-DDP and [Pt(dien)Cl]C1, respectively (Salles et al., 1983). Thus, a
quantitative inhibition of DNA synthesis in vivo does not appear to correlate with the
cytotoxic and antitumor activities of cis- and trans-DDP. Supporting this view are
results from a study by Ciccarelli and coworkers in which simian virus 40 (SV40)
was used as an in vivo model of chromatin. These authors showed that treatment of
SV40-infected African green monkey CV-1 cells with cis- or trans-DDP caused equal
inhibition of DNA synthesis when equal numbers of platinum adducts were present on
the DNA (Ciccarelli et al., 1985). Results, however, from a subsequent study
directly contradict these findings (Roberts and Friedlos, 1987). This discrepancy may
reflect a technical difference in experimental design (Bruhn et al., 1990).
2. Effects on RNA transcription
The inhibition of DNA synthesis effected by trans-DDP both in vitro and in
cultured cells suggests that the antitumor activity of cisplatin is not derived solely
from its ability to inhibit DNA replication. Another way in which cisplatin may exert
its cytotoxic effects is through inhibition of transcription. RNA synthesis, like DNA
replication, is more critical for a rapidly dividing tumor cell than for a stationary cell
(Mauck and Green, 1973). The effects of cis- and trans-DDP on RNA synthesis have
thus been examined, albeit not as extensively as DNA synthesis, both in vitro and in
vivo.
Prior to the present work, the most definitive examination of the effects of cis-
and trans-DDP on transcription focused on the blocking of RNA polymerases in vitro.
Duplex DNAs containing site-specific platinum adducts were multimerized and then
used as templates in transcription reactions catalyzed by either E. coli RNA
polymerase or the eukaryotic wheat germ RNA polymerase II. The intrastrand 1,2-
d(GpG), 1,2-d(ApG) and 1,3-d(GpTpG) adducts of cis-DDP as well as the interstrand
crosslink formed by either compound irreversibly blocked elongation of nascent RNA
molecules by both polymerases. By contrast, the intrastrand 1,3-d(GpTpG) adduct of
the trans isomer and the monofunctional adduct of [Pt(dien)Cl]Cl could be bypassed
by RNA polymerases allowing elongation of the nascent RNA (Corda et al., 1991;
Corda et al., 1993; Brabec and Leng, 1993). In response to intrastrand adducts,
transcription stopped directly opposite the lesion, whereas elongation was blocked
several nucleotides before the transcription complex reached an interstrand crosslink.
Significantly, inhibition of the polymerase was only observed when a platinum lesion
was present on the transcribed strand. In these same studies, the ability of RNA
polymerase to add a single nucleoside triphosphate to a dinucleotide primer directly
opposite a cisplatin lesion was examined. None of the platinum adducts were an
absolute block to this priming activity (Corda et al., 1992; Corda et al., 1993). The
1,2-d(GpG) cisplatin adduct impeded the single-step addition reaction more effectively
than the 1,2-d(ApG) adduct, indicating that the polymerases could distinguish between
the two structurally similar crosslinks (Corda et al., 1992). This differential
inhibition was attributed to a lower affinity of the polymerase for the 1,2-d(GpG)
adduct containing template, as the apparent Km of the enzyme was increased by - 5-
fold for this substrate compared to that containing the 1,2-d(ApG) adduct. Taken
together, these results indicate that platinum lesions may not only provide a physical
block to the progression of RNA polymerases, but may also alter the properties of the
transcription complex through the distortions they introduce to the DNA duplex.
In addition to blocking RNA polymerase processivity, cisplatin adducts can
also inhibit transcription at the level of initiation. Direct evidence for this conclusion
comes from a recent study in which cis-DDP treatment of cells inhibited binding of a
transcription factor, NF1, to the mouse mammary tumor virus promoter present on a
transiently introduced template (Mymryk et al., 1995). In these same studies, cis-
DDP reduced the changes in nucleosomal organization required for transcription
factor access, but trans-DDP did not. The relative number of DNA adducts formed
in cells after treatment with each platinum isomer was not determined in this
experiment, and thus no direct comparisons between the two compounds can be made
in this regard.
The inhibition by cisplatin of bulk RNA synthesis in cultured human cells and
in murine tumor cells in vivo has been examined. Total RNA and mRNA production
is markedly inhibited by cisplatin, although not to the same degree as DNA synthesis
(Harder and Rosenberg, 1970; Howle and Gale, 1970; Ganeva et al., 1990). The
effect of cisplatin on individual gene expression has also been monitored. A panel of
chimeric marker genes, where the promoter and the reporter gene were independently
varied, were transiently introduced into monkey CV-1 cells, and the cells were then
treated with cisplatin or trans-DDP. Strong differential inhibition of gene expression
is observed at pharmacologically relevant doses of the drug, and the greatest
inhibition correlates with the strongest promoters (Evans and Gralla, 1992a). These
differential effects were not observed for trans-DDP, which was only weakly
inhibitory to transcription from all promoters examined. Inhibition of gene expression
was greater for longer genes, which likely reflects the greater number of potential
sites for cisplatin modification. In similar studies carried out in human cells, cisplatin
caused a surprising induction of gene expression from certain promoters, including the
HIV long terminal repeat (LTR) sequence, and inhibited gene expression from others
(Evans and Gralla, 1992b). Cisplatin-stimulated expression from the HIV-LTR
promoter (Zoumpourlis et al., 1990) and from the human c-myc promoter (Spandidos
et al., 1991) has been reported by others. As the mechanism responsible for this
stimulation was not investigated, it remains unclear whether it was a direct result of
cisplatin modification of the gene, or was an indirect consequence of a general
cellular response, such as induction of transcription regulatory factors, to cisplatin
treatment.
The observations discussed above support the possibility that inhibition of
RNA synthesis may contribute to the selective cytotoxic and antitumor activities of
cisplatin. Although bulk RNA synthesis is less effected by cisplatin than DNA
synthesis, it is reasonable to speculate that even in the absence of measurable
reductions in RNA synthesis, changes induced in the delicate balance of cellular gene
expression by cisplatin could be detrimental to a cell. Of relevance in this context are
studies showing that cis-DDP treatment of L1210 cells causes arrest in the G2 phase
of the cell cycle, and that the arrested cells subsequently undergo apoptosis (Sorenson
and Eastman, 1988a; Sorenson et al., 1990). It has been proposed, therefore, that
cisplatin DNA adducts may trigger apoptosis by inhibiting either overall gene
expression, or a critical gene required for passage to mitosis (Sorenson and Eastman,
1988b).
3. Repair of platinum DNA adducts
Considering that platinum DNA adducts mediate cisplatin cytotoxicity, whether
it be through inhibition of replication, transcription, or by some other mechanism, the
repair of platinum lesions is an important way for a cell to increase its probability for
survival. Indeed, studies in E. coli have demonstrated that strains deficient in
Uvr(A)BC excision repair (uvrA, uvrB, uvrC) and recombinational repair (lexl, recA,
recB, recC) are hypersensitive to cisplatin toxicity (Beck and Brubaker, 1973; Alazard
et al., 1982). Such strains are also hypersensitive to trans-DDP at high doses,
indicating that both repair pathways play a role in repair of trans-DDP damage as
well (Alazard et al., 1982). Survival of cisplatin modified plasmids was greater in
recA mutant strains compared with uvrB mutant strains, indicating that the recA-
dependent pathway plays a minor role in cisplatin repair (Husain et al., 1985; Popoff
et al., 1987). In these same studies the induction of the SOS response, which serves
to increase expression of excision repair proteins, increased survival of cis- but not
trans-DDP modified plasmid. This result suggested that DNA adducts of the two
isomers may, to some extent, be repaired differently in E. coli.
Excision repair acts on a broad range of DNA damage, including bulky
adducts formed by psoralen, benzo[a]pyrene, and UV light. The mechanism of
Uvr(A)BC excision repair in E. coli has been well characterized (Sancar, 1996). In
this system a dimer of UvrA in complex with UvrB binds to the site of damage,
followed by an ATP-dependent conformational change that leads to dissociation of
UvrA and the formation of a stable UvrB-DNA complex. UvrC is then recruited and
together, UvrB and UvrC incise the eighth phosphodiester bond 5' and the fourth or
fifth phosphodiester bond 3' to the cisplatin adduct (Beck et al., 1985). UvrD
(helicase II) subsequently facilitates release of the 12-13 nucleotide fragment, DNA
polymerase I fills in the gap, and the remaining nick is sealed by ligation. This so
called "excinuclease" activity of Uvr(A)BC on platinum DNA damage has been
examined in vitro. Plasmid DNA globally modified with cis- or trans-DDP was a
substrate for incision by the Uvr(A)BC excinuclease, although the excinuclease was
more active on cis-DDP modified plasmids (Beck et al., 1985; Popoff et al., 1987).
The relative activity of Uvr(A)BC for individual platinum adducts was examined using
substrates containing site-specific adducts of [Pt(dien)Cl]C1; the relative rates of
excision by Uvr(A)BC were found to be in the order 1,3-d(GpNpG) >
monofunctional > 1,2-d(ApG) > 1,2-d(GpG) (Page et al., 1990). In a more recent
study using site-specific adducts of cisplatin, the 1,2-d(GpG) crosslink was reported to
be incised 3.5-fold more efficiently than a 1,3-d(GpCpG) crosslink (Visse et al.,
1994). This inconsistency may be a reflection of the different platinum complexes
used in the two studies.
In mammalian cells, as in E. coli, nucleotide excision repair is believed to be
the primary mechanism for repair of platinum damage. Excision repair in mammalian
cells is far more complex than in E. coli; 13-16 polypeptides are required for the
excision step, and a total of - 30 polypeptides are involved in the entire repair process
(Sancar, 1996). The mechanism of mammalian excision repair is rapidly being
elucidated, and was recently the subject of several excellent reviews (Wood, 1996;
Sancar, 1996). The autosomally recessive inherited disorder xeroderma pigmentosum
(XP) is caused by defects in nucleotide excision repair and is characterized by
extreme UV sensitivity and a high predisposition to skin cancers. Mammalian
excision repair genes include those that complement the seven XP complementation
groups A through G, as well as the ERCC (excision repair cross-complementing)
genes. As in E. coli, the basic mechanism involves recognition, dual incisions on the
damaged strand, excision of an oligomer and resynthesis through the resulting gap.
Specifically, XPA protein in complex with human single-stranded binding protein
(HSSB) is responsible for damage recognition. Recognition signals for recruitment of
TFIIH, a protein complex that contains both XPB and XPD and has dual functions in
transcription and excision repair; the helicase activity of TFIIH is thought to open the
duplex at the lesion site. XPG and the ERCC1-XPF heterodimer make incisions 3-9
phosphodiester bonds 3' and 16-25 phosphodiester bonds 5' to the lesion,
respectively, yielding a repair patch - 25-30 nucleotides long. DNA polymerase 6 or E
carries out the gap-filling repair synthesis with the aid of proliferating cell nuclear
antigen (PCNA), an accessory factor that likely assists in initiation of synthesis at the
3'-OH of the gap. Very recently, mammalian excision repair has been reconstituted
in vitro with purified components (Aboussekhra et al., 1995), a step that will
undoubtedly facilitate further elucidation of this complex mechanism.
As was found for excision repair deficient E. coli mutants, mammalian cells
deficient in excision repair are hypersensitive to cisplatin (Poll et al., 1984; Hoy et
al., 1985; Dijt et al., 1988). XPA cells are three- to four-fold more sensitive to
cisplatin compared to normal repair proficient cells as measured by the dose required
to reduce survival to 37% of control untreated cells (Poll et al., 1984; Dijt et al.,
1988). A nucleotide excision repair-deficient rodent cell line UV5 is similarly three-
fold hypersensitive to cisplatin, while the rodent UV20 cell line, which is deficient in
the ERCC1 gene, is 50-fold more sensitive to cisplatin than wild type cells as
measured by the lowest concentration of drug that produced measurable loss in
survival (Hoy et al., 1985). Studies monitoring repair indirectly through the
reactivation of a cisplatin modified reporter gene transfected into mammalian cells
found less gene reactivation in excision repair deficient cells than in normal cells,
suggesting that less efficient repair of cisplatin adducts occurred (Chu and Berg,
1987; Sheibani et al., 1989). Experiments in which the level of cisplatin DNA
adducts present in the genomic DNA of cisplatin treated cells was monitored directly
over time has provided further demonstration that XPA cells are indeed deficient in
repair of cisplatin intrastrand adducts (Dijt et al., 1988). The rodent UV20 cell line
defective in the ERCC1 gene was less efficient than normal cells at removal of the
minor interstrand crosslink (Meyn et al., 1982), a result consistent with the possible
dual role for this gene product in recombinational repair (Sancar, 1996). The rate of
nucleotide excision repair of cisplatin adducts in mammalian cells has also been
examined. Global removal of intrastrand adducts in repair proficient cells occurs
most rapidly in the first 4-6 hours after treatment, followed by slower removal over
time, and repair kinetics for the individual crosslinks 1,2-d(GpG), -d(ApG) and 1,3-
d(GpNpG) (where N is any nucleotide) were found to be similar (Eastman and
Schulte, 1988; Dijt et al., 1988). Excision repair deficient XPA cells are lacking in
this fast repair process, although some slow repair is detected over a 24 h time period
(Dijt et al., 1988).
The relative repair efficiency of cisplatin and trans-DDP DNA damage in
mammalian cells has been examined in several studies. In vitro excision repair assays
carried out on globally damaged plasmid DNA using human cell extracts
demonstrated that both cisplatin and trans-DDP DNA damage stimulated repair
synthesis. Extracts of XP cells were deficient in repair synthesis for either
compound, indicating that excision repair operates on DNA adducts formed by both
platinum isomers (Hansson and Wood, 1989; Hansson et al., 1990). Interestingly,
greater repair synthesis was stimulated by trans-DDP modified DNA in this in vitro
system (Hansson and Wood, 1989). A study examining the inhibitory effects of
platinum DNA adducts on DNA replication in vitro found that pre-incubation of
platinum modified substrates with cell extracts resulted in a 30% restoration of DNA
replication for trans-DDP modified template but not for cisplatin damaged DNA
(Heiger-Bernays et al., 1990). These results suggested that DNA adducts of trans-
DDP may be preferentially repaired over those of cisplatin, and it has been postulated
that trans-DDP may be less cytotoxic for this reason. Studies in vivo, however, have
yielded conflicting views. A study in which levels of cis- and trans-DDP adducts in
monkey cells following treatment with either compound were monitored over time
found results suggesting that trans-DDP adducts are preferentially repaired (Ciccarelli
et al., 1985). Later studies by Roberts and Friedlos challenged that conclusion,
proposing that the appearance of differential repair in the Ciccarelli report was
possibly caused by the different reactivities of the two isomers toward cellular DNA,
and by the subsequent greater inhibitory effects of cis-DDP compared with trans-DDP
adducts to DNA synthesis and cell growth (Roberts and Friedlos, 1987). The Roberts
study, however, was carried out in an environment in which the nature of the
platinum compounds interacting with cells was uncertain and, as a consequence, the
two studies may not be directly comparable (Sherman and Lippard, 1987). Whether
cis- and trans-DDP DNA adducts are differentially repaired remains unresolved.
The repair of individual DNA adducts formed by cisplatin has also been
examined. Results from an early in vitro excision repair assay indicated that repair
synthesis carried out on cisplatin modified DNA resulted from removal of the minor
adducts of cisplatin (Calsou et al., 1992). Consistent with this prediction, the 1,3-
d(GpTpG) cisplatin adduct positioned site-specifically in a circular DNA duplex
stimulated repair synthesis in an in vitro excision repair assay mediated by human cell
extracts, while no repair activity was detected for the major cisplatin 1,2-d(GpG)
adduct (Szymkowski et al., 1992). In independent studies, excision by human cell
extracts of the 1,2-d(GpG) as well as the 1,2-d(ApG) cisplatin crosslink was
observed; consistent with the previous report, however, the cisplatin 1,3-d(GpTpG)
intrastrand adduct was excised most efficiently (Huang et al., 1994; Zamble et al.,
1996). A site-specific interstrand cisplatin crosslink was not excised by the human
excinuclease in this in vitro system. A reconstituted excision repair system containing
highly purified repair components yielded similar results to those obtained with human
cell extracts (Zamble et al., 1996). Further analysis of the human excinuclease
activity in vitro revealed incision at the 16th phosphodiester bond 5' to the adduct and
at the 9th phosphodiester bond 3' to the cisplatin lesion, resulting in an excised
oligomer 26 nucleotides in length (Moggs et al., 1996). Taken together, these
findings suggest that structural distortions may determine the relative excision repair
rates of various cisplatin adducts. Moreover, they suggest that inefficient repair of
the major 1,2-d(GpG) intrastrand adduct may contribute to the antitumor activity of
cisplatin.
Less than a decade ago it was revealed that transcribed DNA is repaired more
efficiently than nontranscribed DNA, and that this effect is predominantly due to
preferential repair of the transcribed strand (Mellon et al., 1987). This phenomenon,
known as transcription-coupled repair, is the subject of recent reviews (Drapkin et al.,
1994; Friedberg, 1996). The major factor contributing to this process is believed to
be the pausing of RNA polymerase II at inhibitory lesions in DNA. In E. coli, the
transcription-repair coupling factor (TRCF) mediates such repair by specifically
recognizing the stalled polymerase and recruiting the UvrA2B complex to the site of
damage (Selby and Sancar, 1993). In humans, the CSA and CSB gene products are
necessary for transcription-coupled repair, and a defect in either gene results in
Cockayne's syndrome (CS) (Hanawalt, 1994). Although the mechanism of
transcription-coupled repair in humans is not known, it is believed that CSB may
perform a function analogous to TRCF in E. coli. Interestingly, some mutations in
XPB and XPD, proteins that play dual roles in transcription and repair as components
of the TFIIH complex, can also give rise to CS.
Several studies have demonstrated that cisplatin damage is a substrate for
transcription-coupled repair. Cisplatin intrastrand adducts are repaired more
efficiently from actively transcribed genes than from transcriptionally silent regions of
the genome and, moreover, from the transcribed strand as compared with the
nontranscribed strand (Jones et al., 1991; May et al., 1993; Larminat et al., 1993).
More efficient repair of cisplatin interstrand crosslinks from an actively transcribed
gene was observed when cells were treated with low doses of the drug (Larminat et
al., 1993). It is noteworthy that in these studies cleavage by Uvr(A)BC excinuclease
was used to monitor the presence of cisplatin intrastrand adducts in DNA. Hence it
remains possible that only those intrastrand adducts efficiently detected by the enzyme
are in fact substrates for this repair process. A novel technique for gene-specific
detection of cisplatin adducts was recently described that may prove useful in future
studies examining this phenomenon (Rampino and Bohr, 1994).
4. Recognition by cellular proteins
a. Identification of cisplatin damage recognition proteins
Research has more recently focused on a class of eukaryotic proteins that binds
specifically to cisplatin modified DNA. Such proteins were initially discovered in
studies aimed at isolating DNA repair enzymes, a logical approach in that damage
recognition is reasonably the initial step in repair. Initial studies using cisplatin
modified DNA probes in gel mobility shift assays revealed several factors in human
cell extracts that specifically recognized cisplatin modified DNA (Chu and Chang,
1988; Donahue et al., 1990; Chao et al., 1991; Andrews and Jones, 1991).
Complementary southwestern analysis experiments indicated that such cisplatin
damage recognition proteins included both high molecular weight (90-100 kDa) and
low molecular weight (- 30 kDa) species (Toney et al., 1989; Chao et al., 1991;
Andrews and Jones, 1991). Interestingly, DNA modified by trans-DDP or
[Pt(dien)Cl]Cl was not bound by these factors, suggesting that the cis geometry was
required for recognition (Toney et al., 1989; Donahue et al., 1990). As a means to
identify such proteins, Toney and colleagues employed cisplatin modified DNA to
screen a human B-cell cDNA library (Toney et al., 1989). This approach led to the
isolation of a full length clone encoding an 81 kDa protein, which was named
structure-specific recognition protein 1 (SSRP1) for lack of a known function. The
predicted amino acid sequence revealed a 75 amino acid region with 47% homology
to a similar region in the abundant 24.5-kDa chromosomal protein termed high-
mobility-group protein 1 (HMG1) (Bruhn et al., 1992). It has since been revealed
that SSRP1 is the homolog of a mouse protein, T160, which binds to recombination
signal sequences required for V(D)J recombination (Shirakata et al., 1991). A formal
link, however, to immunological processes has not yet been established.
The discovery that SSRP1 contained this highly conserved region, commonly
referred to as the HMG-box or -domain, suggested that HMG1 would also recognize
cisplatin modified DNA. Indeed, subsequent studies showed that both HMG1 and
HMG2 bound to cisplatin modified DNA, and that a mixture of HMG1 and HMG2
were in fact responsible for the - 30 kDa species observed previously in southwestern
blots (Pil and Lippard, 1992; Hughes et al., 1992). Purified recombinant rat HMG1
bound specifically to cisplatin intrastrand 1,2-d(GpG) and 1,2-d(ApG) crosslinks (Kd
= 3.7 x 10-' M vs. 3.2 x 10-' M for unmodified DNA), but lacked specificity for 1,3-
d(GpTpG) cisplatin adducts (Pil and Lippard, 1992). Consistent with previous
observations, HMG1 displayed no affinity for DNA damaged by the therapeutically
ineffective analogs trans-DDP or [Pt(dien)Cl]C1. Thus the 1,2-intrastrand crosslinks
formed exclusively by therapeutically active platinum compounds are preferentially
recognized by HMG1. Interestingly, it was reported recently that HMG1 also binds
to the minor cisplatin interstrand crosslink, but not to that formed by trans-DDP
(Kasparkova and Brabec, 1995), further underscoring the selectivity of HMG1 for
cisplatin DNA adducts. The HMG-box domain is believed to mediate the recognition
of cisplatin-modified DNA. Strongly supporting this view, an isolated HMG-box
domain of HMG1 was found to bind the 1,2-d(GpG) cisplatin adduct with an affinity
equal to that of HMG1 itself (Chow et al., 1995).
The HMG-box is in fact a novel signature DNA binding motif that defines a
large and rapidly growing family of proteins (Baxevanis and Landsman, 1995). In
addition to SSRP1 and HMG1, HMG-box proteins that have been shown to bind
cisplatin modified DNA currently include human upstream binding factor (hUBF)
(Treiber et al., 1994), testis determining factor (SRY) (E. Trimmer, manuscript in
preparation), mitochondrial transcription factor (mtTFA) (Chow et al., 1995), the S.
cerevisiae transcriptional regulator Ixrl (Brown et al., 1993), and the isolated HMG
domains from HMG1, mSRY and lymphoid enhancing factor (LEF-1) (Chow et al.,
1994). Many HMG-box proteins, such as hUBF, LEF-1, SRY and mtTFA, are
specific regulators of transcription; others, such as HMG1, have as yet undefined
functions, although roles for HMG1 in DNA replication, gene transcription and in
modulating chromatin structure have been suggested (Einck and Bustin, 1985). There
is no indication to date that HMG-box proteins are involved in repair processes,
suggesting that any roles these proteins might play in cisplatin cytotoxicity are likely
to be unrelated to DNA repair.
While no HMG-box proteins have been implicated in DNA repair, additional
non-HMG-box proteins that bind to cisplatin modified DNA have been identified,
some of which do have roles in repair. Such proteins include a 125-kDa UV-damage
recognition protein identified for its ability to recognize both UV and cisplatin DNA
damage (Chu and Chang, 1988), human single-stranded binding protein (HSSB or
RPA) (Clugston et al., 1992), and human Ku autoantigen (Turchi and Henkels, 1996).
Recognition of cisplatin damage by HSSB/RPA is consistent with this protein's role in
the incision step of nucleotide excision repair. The UV-damage recognition protein
was named XPE protein owing to its specific absence in a subset of XPE cell lines
(Chu and Chang, 1990; Keeney et al., 1992; Kataoka and Fujiwara, 1991). XPE is
also believed to be involved in excision repair, although its precise role remains
unclear (Sancar, 1996). Ku protein has been implicated in double-strand break repair
and V(D)J recombination (Finnie et al., 1995). The relevance of Ku recognizing
cisplatin DNA damage is unknown, although it is conceivable that the structure of
cisplatin damaged DNA resembles an intermediate in the immunoglobulin gene
rearrangement.
b. Structural basis for recognition by HMG-box proteins
Why do HMG-box proteins recognize cisplatin DNA adducts? All HMG-box
proteins have the common feature of binding to DNA involved in structural
deformations (Lilley, 1992). For example, HMG1 binds to cruciform structures and
unwinds negatively supercoiled DNA (Bianchi et al., 1989), and the HMG domains of
SRY and HMG1 bind to four-way junction DNA (Ferrari et al., 1992; Bianchi et al.,
1992). Hence the duplex DNA bending and unwinding induced by cisplatin adducts
likely provide the structural signal for HMG box protein recognition (Donahue et al.,
1990; Bruhn et al., 1992). In addition to recognizing pre-bent structures, HMG-box
proteins can induce dramatic bends in linear DNA sequences, as has been shown for
SRY, HMG1 and LEF-1 (Ferrari et al., 1992; Pil et al., 1993; Giese et al., 1992).
Indeed, several HMG-box proteins, upon binding to DNA that contained a site-
specific 1,2-d(GpG) adduct, were shown to cause further DNA distortion, resulting in
a 50-90o bend centered in the vicinity of the platinum crosslink (Chow et al., 1994).
Thus the bending afforded by a cisplatin adduct may facilitate the conversion of
duplex DNA into the preferred binding configuration of an HMG-domain protein
(Chow et al., 1995).
Recently, solution structures of the HMG-domains from several HMG-domain
proteins have been determined by NMR spectroscopy. The HMG domain B from
HMG1 in the absence of DNA was found to be made up of three a helices that form
an L shape, with an 800 angle between the two arms that is defined by a cluster of
conserved aromatic residues (Read et al., 1993; Weir et al., 1993). A structure of
the SRY-HMG domain bound to its putative DNA target sequence found an analogous
L-shaped configuration (Werner et al., 1995). DNA binding occurred on the concave
surface of the L, and DNA contacts were made within a significantly widened minor
groove. The DNA helix was severely underwound, bent by - 70-80o towards the major
groove, and the DNA structure displayed features intermediate between those of A-
and B-DNA. A very similar structure was found for the LEF-1 HMG domain
complexed with its cognate DNA (Love et al., 1995). This novel structure induced in
DNA upon binding by these HMG domains is strikingly similar to the structure
solved for a duplex DNA dodecamer containing a 1,2-d(GpG) cisplatin adduct (vide
supra) (Takahara et al., 1995). Hence these studies reinforce the notion that DNA
distortions induced by cisplatin adducts resemble the naturally occurring binding sites
and binding configurations preferred by this class of proteins.
c. Roles for cisplatin damage recognition proteins
The selective affinity of HMG proteins for the DNA adducts of therapeutically
active platinum compounds (Toney et al., 1989; Pil and Lippard, 1992) suggests a
role for such proteins in potentiating cisplatin cytotoxicity. Several models to explain
the possible involvement of HMG box proteins in the mechanism of action of cisplatin
have been proposed. One model suggests that binding of these proteins to cisplatin
DNA adducts prevents access to the lesions by DNA repair enzymes; decreased repair
of cisplatin DNA adducts would result in persistence of the signal that triggers cell
death. Supporting this hypothesis are results from in vitro excision repair assays.
Preincubation of HMG1 or mtTFA with substrates containing site-specific cisplatin
adducts effectively block the 1,2-d(GpG), but not the 1,3-d(GpTpG), adduct from
repair by the human excinuclease present in cell extracts (Huang et al., 1994).
Similar inhibition by HMG1 was observed when repair was mediated by a
reconstituted system containing highly purified human repair factors (Zamble et al.,
1996). Further evidence was obtained by using a yeast strain defective in the HMG-
box protein Ixrl. Interruption of the IXR1 gene desensitized yeast cells by two-fold to
cisplatin; by contrast, no differential sensitivity was observed to trans-DDP or UV
light (Brown et al., 1993). Resistance of the ixrl strain was associated with a three-
fold decrease in accumulation of cisplatin DNA adducts. Further, an examination of
the effects of Ixrl on cisplatin sensitivity in various excision repair backgrounds
revealed a dependence upon a functional excision repair recognition complex
(McA'Nulty and Lippard, 1996), suggesting that Ixrl blocked the cisplatin adducts
from the repair machinery. Taken together, these studies support the view that HMG
proteins may potentiate cisplatin cytotoxicity by binding to cisplatin DNA lesions,
thereby facilitating their persistence in DNA.
A second model stems from the identification of hUBF, a critical regulator of
ribosomal RNA synthesis, as one of the HMG box proteins that recognizes cisplatin
adducts. hUBF binds to a cisplatin 1,2-d(GpG) adduct (Kd(app) = 60 pM) and to its
cognate rRNA promoter sequence (Kd(app) = 18 pM) with comparable affinities,
leading to the proposal that cisplatin adducts may act as molecular decoys for the
transcription factor in vivo (Treiber et al., 1994). Thus by a "transcription factor
hijacking" mechanism, cisplatin may deplete cells of a necessary resource for growth.
Supporting this model, levels of cisplatin adducts well below that found in cells of
patients effectively antagonized hUBF-promoter interactions in footprinting assays
(Treiber et al., 1994). Moreover, cisplatin modified DNA successfully inhibited
transcription from the hUBF promoter in a fully reconstituted in vitro transcription
system, while DNA modified by trans-DDP did not (X.Q. Zhai, manuscript in
preparation). By contrast, in vivo experiments testing the hijacking model with the
transcriptional regulator Ixrl in yeast found that Ixrl was not titrated away from its
promoter, Cox5b, by cisplatin adducts following treatment with the drug (McA'Nulty
et al., 1996). It is possible, however, that the relatively low affinity (Kd = 2.4 x 10-7
M) and modest specificity (- 10-fold over unmodified DNA) of Ixrl for a cisplatin
adduct (McA'Nulty et al., 1996) render it a poor candidate for the hijacking
mechanism.
Yet a third way in which cellular proteins that associate with cisplatin DNA
damage might affect cisplatin cytotoxicity is by initiating the repair of cisplatin
lesions. As already mentioned, no HMG-box proteins have been implicated in DNA
repair. Other cisplatin recognition proteins, including HSSB and XPE, do have roles
in repair. Interestingly, XPE protein was reported to be present at 5-fold increased
levels in some cisplatin resistant tumor cell lines, cells in which increased repair of
cisplatin damage was also found (Chu and Chang, 1990). An - 130 kDa cisplatin
damage recognition protein was likewise found to be overexpressed in a cisplatin
resistant cell line, and was inducible upon cisplatin treatment (Chao et al., 1991);
although the species was not identified, the size and behavior of the protein suggest it
may be XPE protein. A recent study reports that cisplatin treatment of human cells
caused induction of a protein that binds selectively to UV-damage, and that this
cisplatin-responsive induction is higher in cisplatin resistant cells than in normal cell
lines (Vaisman and Chaney, 1995). These observations suggest that such cell lines
were resistant by virtue of an increased capacity to repair cisplatin damage. This
subject is discussed further in the next section. By contrast, there has been only one
report to date of increased levels of HMG-box proteins (HMG1 and 2) in cisplatin
resistant cells (Billings et al., 1994). Moreover, no human HMG-box proteins other
than SRY (Goldmacher et al., 1986) are known to be differentially expressed in
testicular tissue. It is noted, however, that a mouse HMG-box protein SOX5 has
been shown to be overexpressed in testicular tissue (Denny et al., 1992) and a testis-
specific mouse HMG-box (tsHMG) protein has been identified (Boissonneault and
Lau, 1993). Also of relevance, levels of a rapidly migrating HMG2 subtype have
been reported to be significantly elevated in rat testicular tissue as compared to 15
other rat tissues (Bucci et al., 1985). The physiological relevance of HMG-box
protein recognition of cisplatin damage awaits correlations between levels of these
proteins in human cells/tissues and sensitivities to the drug.
5. Resistance to cisplatin
The development of resistance to cisplatin is a significant problem in cisplatin-
based chemotherapy, representing the major factor responsible for treatment failure.
There are two types of cisplatin resistance, the first being an acquired phenomenon
that arises following exposure to the drug, and the second being an intrinsic resistance
of a patient's tumor to cisplatin from the very beginning of treatment. Numerous
cisplatin resistant cell lines, most of which were developed by repeated or continuous
exposure to the drug in culture, have been valuable in the elucidation of the
mechanisms of cisplatin resistance. Tumor cells made resistant in vivo have also been
studied, and although far less available, may more faithfully represent the clinical
situation. For example, cells treated in culture with cisplatin often acquire a much
higher levels of resistance than that of tumors in vivo (the latter are generally on the
order of 2-3-fold more resistant) (Enns and Howell, 1991), implying that mechanisms
may be operative that are not directly relevant to the clinical situation. Another
caveat to examining resistance mechanisms in any cell line is that some mechanisms
may operate only at the level of the organism, and not at the cellular level. This is
illustrated in a study in which a murine mammary tumor acquired resistance to
cisplatin in vivo, but when cells from the tumor were cultured in vitro they were no
longer resistant to the drug (Teicher et al., 1990). Interestingly, when the tumor was
implanted into other host animals, it was capable of altering cisplatin
pharmacokinetics, suggesting that the tumor secreted hormonal substances that
produced a change in drug distribution. In a subsequent study, the resistant
phenotype of these in vivo-derived tumor cells was rescued in culture when the cells
were grown as three-dimensional multicellular tumor spheroids that more closely
mimic in vivo-like conditions (Kobayashi et al., 1993). The mechanism underlying
this multicellular resistance remains to be established.
Despite the above caveats, studies of cisplatin resistant cell lines have revealed
numerous mechanisms that contribute to this phenomenon, including 1) reduction in
cellular accumulation; 2) elevated levels of molecules that sequester cisplatin, such as
glutathione and metallothionein; 3) increased capacity to repair cisplatin DNA
adducts; and 4) changes in expression of regulatory proteins, such as oncogenes and
tumor supressors (Andrews and Howell, 1990; Scanlon et al., 1991; Timmer-Bosscha
et al., 1992). Resistance is generally believed to be multifactorial, and thus one or
more of these mechanisms may be operative in a particular resistant tumor or cell
line.
a. Cisplatin accumulation
Given that DNA adducts are believed to mediate cisplatin cytotoxicity, limiting
the number of cisplatin adducts formed in DNA is a logical way that cells can
decrease their susceptibility to the drug. One mechanism by which cells may achieve
this end is through limited drug uptake. Decreased accumulation of cisplatin has been
consistently observed in resistant cell lines (Andrews and Howell, 1990; Scanlon et
al., 1991), although these decreases are generally small, even when levels of
resistance are high. Changes in accumulation have in some studies been specifically
attributed to a decrease in influx of cisplatin, as decreased accumulation could be
observed almost immediately after treatment (Waud, 1987; Hromas et al., 1987).
Despite the possible importance to cisplatin resistance, the mechanism underlying
these changes in accumulation remains unknown. In fact, the mechanism by which
cisplatin enters a cell, whether through passive diffusion or active membrane
transport, is also a matter of debate, and was recently the subject of review (Gately
and Howell, 1993).
b. Sequestration by sulfur-containing molecules
A second mechanism by which cells may limit the formation of cisplatin
adducts is by increasing levels of sulfur-rich molecules that can sequester cisplatin
before it reaches DNA. Such molecules include metallothionein and glutathione.
Metallothionein and glutathione have both been shown to interact with cisplatin in
cells, and in either case a significant proportion of cytoplasmic cisplatin (25 % and
60%, respectively) was found to be complexed by the molecule (Sharma and
Edwards, 1983; Ishikawa and Ali-Osman, 1993). Studies examining levels of
metallothionein and glutathione in normal and cisplatin resistant cell lines, however,
indicate that these molecules are overexpressed in some but not all resistant cells.
Metallothioneins function in the detoxification of heavy metals, such as
cadmium and mercury. A ten-fold overexpression of metallothionein in mouse cells
generated four-fold resistance to cisplatin, directly demonstrating that metallothionein
can affect cisplatin toxicity (Kelley et al., 1988). Supporting this notion, cells
containing elevated levels of metallothionein and demonstrating resistance to cadmium
were cross-resistant to cisplatin (Andrews et al., 1987; Bakka et al., 1981).
Moreover, tumor cell lines that acquired resistance to cisplatin in vitro overexpress
metallothionein (Kelley et al., 1988). Levels of metallothionein mRNA also correlate
with resistance in human lung cancer cell lines (Kasahara et al., 1991). However, in
other cell lines, levels of metallothionein do not correlate with resistance (Sheibani et
al., 1989) and in one instance elevated levels of metallothionein are actually
associated with an increase in sensitivity to cisplatin (Koropatnick and Pearson, 1993).
In the case of glutathione, similar observations have been made. Increasing
glutathione levels in a normal lung cell line by 50% causes a 1.4-fold decrease in
cisplatin sensitivity, demonstrating that glutathione also can alter cisplatin sensitivity
(Russo et al., 1986). Examination of ovarian tumor cell lines made 30-100-fold
resistant to cisplatin in culture revealed a 13-50-fold increase in glutathione levels
compared to their cisplatin-sensitive parent cell line (Godwin et al., 1992). Cell lines
displaying more physiologically relevant levels of cisplatin resistance (six-fold) have
also been shown to contain elevated glutathione levels (three-fold) (Hospers et al.,
1988) and depletion of glutathione with the inhibitor buthionine sulfoximine sensitizes
both normal and resistant cells to cisplatin (Hamilton et al., 1985). However, as is
the case for metallothioneine, many resistant cell lines display no changes in
glutathione levels (Chao et al., 1992; Kelley et al., 1988). Hence there appears to be
some, but variable, correlation between cisplatin resistance and elevated glutathione or
metallothionein levels.
c. DNA repair capacity
An alternative strategy that cells may use to reduce levels of cisplatin DNA
adducts, and thus acquire resistance to the drug, is to increase their capacity to repair
cisplatin damage. Levels of repair in normal and cisplatin resistant cell lines have
been extensively examined (Chu, 1994; Zamble and Lippard, 1995). In several
studies, ovarian cancer cell lines made resistant to cisplatin in culture are 2-fold more
efficient at repairing cisplatin damage in cellular DNA (Masuda et al., 1988; Masuda
et al., 1990) as well as in transfected plasmid DNA (Parker et al., 1991).
Examination of a testicular tumor cell line and a 5.6-fold cisplatin-resistant variant
derived in vitro revealed that total cisplatin adducts are removed from DNA
significantly faster in the resistant cells than in the parent line (Kelland et al., 1992).
Cell lines that display an intrinsic resistance to cisplatin also have increased levels of
cisplatin-damage repair (Scanlon et al., 1991; Dabholkar et al., 1992b). Increases in
cisplatin adduct repair have been observed in resistant variants of the murine leukemia
L1210/0 cell line (Eastman and Schulte, 1988; Sheibani et al., 1989); it has
subsequently been revealed, however, that the apparent increased repair capacity was
actually due to the spontaneous reversion in the resistant cells of a previously
unknown nucleotide excision repair defect for the XPG gene in the parental cell line
(Vilpo et al., 1995). Indeed, repair is not always associated with resistance (Tashiro
and Sato, 1992). In one resistant cell line cisplatin repair is actually found to be
increased (Hill et al., 1992).
Possible correlations between cisplatin repair and resistance have been
examined in tumor tissue as well. Levels of repair capacity in tumor biopsies from
untreated ovarian cancer patients were measured using an in vitro repair assay and
found to vary by up to 10-fold; this differential capacity for cisplatin adduct repair
was postulated to be responsible for the variability in clinical response to cisplatin
therapy (Jones et al., 1994). In another study a 2.8-fold increase in repair of cisplatin
damage was found in cells from tumor tissue obtained after failed cisplatin therapy
compared to cells from the same tumor before treatment (Ali-Osman et al., 1994).
Interestingly, cisplatin resistance and increased repair in this tumor tissue was
associated with elevated levels of DNA polymerase / (Pol 3), a common observation
for cisplatin resistant cell lines (Scanlon et al., 1991). Although Pol / is not thought
to be involved in DNA repair synthesis, it has been reported to be the only human
DNA polymerase capable of efficient replication past a cisplatin 1,2-d(GpG) adduct
(Hoffmann et al., 1995). Thus increased expression of Pol / may help cells to
tolerate cisplatin damage by facilitating replicative bypass of the DNA lesions.
Expression levels of proteins involved in excision repair are also correlated with
cisplatin resistance. In tumor tissue from ovarian cancer patients, mRNA of the
human nucleotide excision repair gene ERCC1 is higher in tissue from patients that
are clinically resistant to the drug (Dabholkar et al., 1992a). Elevated levels of the
repair-associated protein proliferating cell nuclear antigen (PCNA) are reported in
cisplatin resistant murine leukemia cell lines (Haneda et al., 1991). As noted in the
preceding section, XPE protein has also been found at increased levels in cisplatin
resistant cell lines (Chu and Chang, 1990). Enhanced DNA repair thus appears to be
a common strategy that cells use to reduce their susceptibility to the drug.
d. Effects of regulatory proteins
More recent research into cisplatin resistance has focused on the expression of
regulatory proteins, such as tumor suppressors and oncogenes. Increased expression
levels of the protooncogenes ras, fos and myc all correlate with cisplatin resistance
(Scanlon et al., 1991). In addition, correlations between resistance and elevated
levels of the p53 tumor suppressor gene product have been reported (Davol et al.,
1996). The p53 gene encodes a nuclear phosphoprotein that, through a cascade of
events, activates G1 cell cycle arrest in response to some forms of DNA damage,
thereby allowing the cell more time to repair its DNA before entering S phase (Ko
and Prives, 1996; Gottlieb and Oren, 1996). In addition, it is thought that p53 may
actually induce excision repair. Enhanced levels of p53 could thus confer cisplatin
resistance by increasing time for repair of cisplatin DNA damage; conversely,
inactivation of p53 may sensitize cells to cisplatin. Consistent with this view,
inactivation of p53 in human fibroblasts by acute expression of human papillomavirus
(HPV), which binds to p53 and targets it for degradation via a ubiquitin-dependent
pathway, rendered the cells 6-9-fold more sensitive to cisplatin (Mirakhur et al.,
1996). Similarly, disruption of p53 in human MCF7 breast cancer cells by using
HPV or a dominant-negative mutant p53 gene sensitizes cells to cisplatin, and this
sensitization is associated with a decreased ability of the cells to repair cisplatin-
damaged plasmid DNA (Fan et al., 1995). Further, mouse embryonal fibroblasts
lacking functional p53 (p5 3 -/ -) were found to be hypersensitive to cisplatin
compared to fibroblasts homozygous (p5 3 +/+) or heterozygous (p5 3 +/-) for wild
type p53.
In addition to its role in the G1-checkpoint, p53 can also activate programmed
cell death, or apoptosis, in response to certain forms of DNA damage, and this
pathway can often override the G1-checkpoint response (Thompson, 1995; White,
1996). p5 3 is in fact required for efficient execution of the apoptotic response
induced by various anticancer drugs (Lowe et al., 1993). Through this pathway,
disruption of p53 could lead to resistance to cisplatin and other DNA damaging
agents. Evidence that p53 can affect cisplatin cytotoxicity via this pathway also
exists. Adenovirus-mediated transfer of the wild type p53 gene into monolayers or
multicellular spheroid tumor cultures of lung cancer cell lines with a homozygous
deletion of p53 markedly increases sensitivity of the cells to cisplatin (Fujiwara et al.,
1994). Further, a relationship between p53 and the development of cisplatin
resistance in ovarian carcinoma cell lines in culture has been demonstrated; these
cisplatin resistant cells were shown to harbor two mutant p53 alleles and displayed
reduced susceptibility to cisplatin-induced apoptosis (Parego et al., 1996).
Interestingly, testicular germ cell tumors, which are exquisitely sensitive to cisplatin
therapy, are unusual in that they rarely exhibit p53 mutations (Peng et al., 1993).
These observations suggest that the preferential sensitivity of testicular tumors to
cisplatin could, in part, be owed to their predominantly wild type p53 genotype.
Figure 2: DNA adduct profiles of cisplatin and trans-DDP. Numbers indicate the
percentage of each adduct compared to the total binding spectrum. In cases where
accurate numbers are not available, the ability to form adducts is indicated by "yes"
or "no".
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Figure 3: The chemical composition of the cisplatin 1,2-d(GpG), -d(ApG), and 1,3-
d(GpTpG) adducts. Structural conformations of these adducts are discussed in the
text and are illustrated in references therein.
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III. DNA ADDUCTS OF CISPLATIN AND ITS TRANS ISOMER
INHIBIT RNA POLYMERASE II DIFFERENTIALLY IN VIVO
A. Introduction
The observation that trans-DDP is equally effective at inhibiting DNA
synthesis as cis-DDP (Harder et al., 1976; Bernges and Holler, 1988; Heiger-Bernays
et al., 1990; Salles et al., 1983; Ciccarelli et al., 1985) suggests that mechanisms
other than the blocking of DNA replication may contribute to the cytotoxic activity of
this anticancer drug. One model to explain the differential cytotoxicities of these two
platinum complexes is that cis-DDP adducts may more effectively inhibit
transcription. The goal of the work summarized in this chapter was to compare
directly the effects of cis- and trans-DDP DNA adducts on RNA synthesis in
mammalian cells. A nonreplicating transient expression vector harboring a
prokaryotic reporter gene under the transcriptional control of a eukaryotic promoter
was modified in vitro to defined levels with either platinum compound and transfected
into human or rodent cell lines. The relative inhibition of RNA synthesis by the two
platinum compounds was evaluated by 1) measuring levels of 0-galactosidase enzyme
activity in extracts made from the transfected cells and 2) recovering nascent 0-gal
mRNA transcripts and directly monitoring transcription elongation through a specific
region of the gene by using ribonuclease protection analysis. In order to eliminate the
variable of excision repair from the experimental system, experiments were carried
out in both nucleotide excision repair proficient and deficient cell lines of both human
and rodent origin, thus allowing examination of transcriptional bypass independently
of excision repair for each platinum compound. Together, these studies facilitated an
estimation of the efficiency with which RNA polymerase II translocates past a single,
representative DNA adduct of cis- or trans-DDP during transcription elongation in
vivo.
The approach adopted in this study afforded two distinct advantages over
alternative strategies wherein cells are directly treated with platinum compounds and
the effects on endogenous gene expression are monitored. First, one can easily
control and precisely quantify the number of platinum adducts introduced into DNA
by either platinum isomer prior to transfection. Second, one can monitor the effects
of platinum adducts on transcription without the confounding effects of platinum
damage to other cellular processes, such as inhibition of DNA replication,
ribonucleotide reduction and induction of apoptosis. This latter point is significant,
considering the complexity of cellular responses elicited upon cisplatin treatment.
Moreover, it is believed that cellular processing of plasmid DNA accurately reflects
that of chromosomal DNA, as evidenced by accurate predictions of the nucleotide
excision repair deficiencies of certain cell lines (Protic-Sabljic and Kraemer, 1985;
Athas et al., 1991). These analyses were made by monitoring repair of UV damage
in nonreplicating transient expression vectors.
B. Materials and Methods
1. Cells and Culture Conditions
HeLa cells (P. Sharp, MIT) were maintained in suspension culture in Joklik-
modified minimal essential medium (MEM) (Gibco), supplemented with 5 % fetal
bovine serum, 100 units/ml of penicillin and 100 /g/ml of streptomycin. HeLa cells
were maintained at a cell density of 5 x 104 - 5 x 105 cells/ml and had a doubling time
of approximately 24 h. The Chinese hamster ovary (CHO) cells designated AA8 and
UV20, obtained from the American Type Culture Collection, were maintained in
suspension culture in a-MEM (Gibco) supplemented with 10% fetal bovine serum,
penicillin and streptomycin. UV20 was derived by mutation of the AA8 cells
(Thompson et al., 1981) and belongs to complementation group 1 (formerly group 2)
(Collins, 1993). CHO cells were maintained at a cell density of 3 x 104 - 4 x 105
cells/ml and had a doubling time of approximately 12-15 h. Human lymphoblastoid
cell lines transformed with Epstein-Barr virus were obtained from the NIGMS Human
Genetic Mutant Cell Repository. Cell line GM02250D is from a donor homozygous
for xeroderma pigmentosum belonging to complementation group A (XPA) and
GM05567 is from the proband's apparently unaffected, but possibly heterozygous,
brother. Cells were maintained in suspension culture in RPMI 1640 medium (Gibco)
supplemented with 15% fetal bovine serum, penicillin and streptomycin, at a cell
density of 2 x 105 - 1.5 x 106 cells/ml, and had a doubling time of approximately 24
2. Plasmids
All plasmids used were incompetent for replication but allowed for the
transient expression of a prokaryotic reporter gene in mammalian cells. CMV-0-gal
(7330 bp; provided by R. Tepper, Harvard Medical School) contains the prokaryotic
0-galactosidase (0-gal) gene inserted between the eukaryotic cytomegalovirus (CMV)
promoter and simian virus 40 (SV40) splice and polyadenylation sequence. PSV2-
CAT (5003 bp) harbors the bacterial chloramphenicol acetyltransferase (CAT) gene
flanked by the SV40 early promoter and splice and polyadenylation sequence (Gorman
et al., 1982). pcDNA3-CAT (6230 bp; Invitrogen) contains the CAT gene between
the CMV promoter and the bovine growth hormone polyadenylation sequence. All
plasmids were isolated from E. coli DH5Ia cultures by using the maxi- or mega-
plasmid purification kits of Qiagen, Inc.
Platination reactions were carried out in 3 mM NaCl, 1 mM Na2HPO 4, pH
7.4, with 200 tg/ml DNA and appropriate platinum compound/DNA molar ratios by
incubating at 370 C for 16 h. Unreacted platinum compound was removed by dialysis
(14 h) against 10 mM Tris-HC1, pH 7.5, 1 mM EDTA. To serve as an unmodified
control, plasmid DNA was subjected to the same treatment in the absence of platinum
compound. Levels of platinum modification were determined by flameless atomic
absorption spectroscopy on a Varian AA1475 instrument equipped with a GTA95
graphite furnace.
3. Transfections
Platinated DNA was transfected into cells by electroporation with a BTX
Electro Cell Manipulator 600. Electroporation conditions for each cell line were first
extensively optimized by independently varying the voltage and capacitance settings;
conditions were chosen that yielded the greatest levels of /-gal expression per pjg of
protein in cell extracts made from the transfected cells. Using optimized
electroporation conditions, duplicate samples of DNA at each platinum level were
transfected into cells. Specifically, HeLa cells in logarithmic growth (2-4 x 105
cells/ml) were concentrated by centrifugation and resuspended at 1.4 x 107 cells/ml in
Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum,
penicillin and streptomycin. Plasmid DNA (20 Itg) and 5 x 106 cells (350 l1) were
mixed, transferred to a sterile 0.2 cm electroporation cuvette, and a single electrical
pulse was immediately delivered to the cells at 245 V, 1150 1F and 13 12. Similarly,
XPA and normal human lymphoblasts (5-8 x 105 cells/ml) were transfected by mixing
40 Itg of plasmid DNA with 2 x 107 cells (350 tl) and electroporating at 125 V, 2700
p/F and 72 Q in RPMI supplemented with 15 % fetal bovine serum, penicillin and
streptomycin. CHO cells (1-2 x 105 cells/ml) were transfected by mixing 5 x 106
cells (350 /il) in a-MEM supplemented with 10% fetal bovine serum, penicillin and
streptomycin with 40 Ig of DNA and electroporating at 165 V, 1150 JF and 13 Q.
Following 10 min at room temperature, transfected cells were transferred to 10 ml of
prewarmed complete medium and incubated in a 10 cm culture dish at 370C for 15,
24 or 48 h (see Results). For RNase protection assays, XPA lymphoblasts were
cotransfected with 32 tg of modified CMV-0-gal and 8 jg of pcDNA3-CAT and cells
were harvested 4 h after transfection.
4. Transient Expression Assays
Cells were harvested by centrifugation, washed once with phosphate-buffered
saline, and resuspended in 100 Il of 0.25 M Tris-HC1, pH 7.8. Cells were lysed by
three cycles of freeze-thaw, and the lysate was centrifuged (14,000g) for 15 min at
40C. The supernatant from cells transfected with CMV-0-gal was assayed for 3-gal
activity by the method of Eustice et al. (Eustice et al., 1991), with slight
modifications. Up to 40 Il of cell lysate was assayed in a 200 /l solution containing
9 mM MgC12, 102 mM 3-mercaptoethanol, 80 mM Na2HPO4, pH 7.3, and 9 mM
chlorophenol red 3-D-galactopyranoside (Boehringer-Mannheim). Assay mixtures
were incubated for a minimum of 30 min at 370C, stopped by the addition of 300 Il
of 0.5 M EDTA, and the absorbance at 570 nm measured with a Beckman DU-65
spectrophotometer. Cell extracts prepared from mock-transfected cells served as
negative controls. The protein concentration of cell extracts was determined by the
Bio-Rad microassay with bovine serum albumin as the protein standard (Bradford,
1976). f-Gal activity for each sample was normalized to the amount of protein
present and is expressed as a percent of the activity determined for an unmodified
control. Percent f-gal activity for duplicate samples at each platinum level were
graphed as a function of platinum adducts/genome. Curves exponentially fitted to the
data were used to determine the platinum level effecting a 63% reduction in f-gal
activity (Do).
In experiments where Hela cells were transfected with PSV2-CAT, the amount
of CAT protein present in cell extracts was measured by using an enzyme
immunoassay for CAT (CAT-ELISA, Boehringer Mannheim) according to the
protocol provided by the supplier. Briefly, up to 40 ,ig of cell extract was placed in
microtiter wells that had been prebound with CAT antibodies. CAT protein bound to
the wells was subsequently hybridized with a second CAT antibody conjugated to
digoxigenin (Anti-CAT-DIG, 2 jLg/ml), and finally with an antibody to digoxigenin
conjugated to peroxidase (Anti-DIG-POD, 150 mU/ml). The amount of peroxidase
enzyme present in each well was determined by using ABTSR-substrate, a
chromophoric substrate to peroxidase. The absorbance of samples in the microtiter
wells was measured at 405 nm in a TitertekR Multiskan 96-well plate reader (Eflab).
The amount of CAT (pg) (determined using a prepared standard curve) was
normalized for the amount of protein present and reported as a percent of unmodified
control.
5. RNA Isolation
Total RNA was isolated by a modification of the method of Chomczynski and
Sacchi (Chomczynski and Sacchi, 1987). Cells were lysed with 0.5 ml of
RNAzolTMB (Biotecx Laboratories), 50 •l of chloroform was added, and the lysate
was centrifuged (14,000g) for 15 min. RNA was purified from the aqueous phase
with 0.5 volumes of isopropyl alcohol and 0.05 volumes of RNA TackTM Resin
(Biotecx). After two washes with 75% ethanol (v/v), RNA was eluted from the resin
with 100 Il H20. To remove possible contaminating plasmid DNA, all RNA samples
were treated with RNase-free DNase (Boehringer Mannheim) for 20 min at room
temperature.
6. Probes
A 215 bp DNA sequence that begins 233 bp and terminates 18 bp 5' to the
stop codon of the f-gal gene was PCR amplified and then inserted downstream of,
and in opposite orientation to, the T7 promoter of pGEM-3zf(-) (Promega). This
pGEM-3zf-O-gal3 construct was linearized with Pst I, and served as template for the
synthesis of a 32 P-labeled antisense RNA probe complementary to the 3' end of the 0-
gal mRNA (OG3; 215 nucleotide protected fragment). Linearized transcription vector
pTri-O-gal (Ambion) served as the template for a second f-Gal antisense RNA probe
complementary to an internal sequence extending from base 934 to 1235 of the 3072
bp of the f-gal gene (fG5; 301 nucleotide protected fragment). Antisense RNA
probes for CAT (152 nucleotide protected fragment) and for human f-actin (127
nucleotide protected fragment) were synthesized from the linearized vectors pTri-CAT
and pTri-f-Actin-125-Human (Ambion), respectively. All antisense radiolabeled
RNA probes were transcribed in vitro by using Ambion MAXIscriptTM . T7 RNA
polymerase (10 U) was incubated with pGEM-3zf-0-gal3 (1 fig), 500 IM ATP, GTP
and TTP, and 5 ftM (a- 32 P)UTP (800 Ci/mmol, 50 tCi) (Amersham) in a 20 tl
reaction at 370C for 1 h. This reaction produced a 246 nucleotide transcription
product containing the 215 nucleotide sequence complementary to the f-Gal gene.
Template DNA was removed by adding RNase-free DNase (2 U) and incubating at
371C for an additional 15 min. pTRI-CAT and pTRI-B-Gal were similarly transcribed
with T7 and SP6 RNA polymerases, yielding 241 and 344 nucleotide transcription
products, respectively. pTri-B-Actin-125-Human was transcribed by using SP6 RNA
polymerase yielding a transcription product of 218 nucleotides, except that the
reaction was carried out in the presence of an additional 150 pM unlabeled UTP in
order to produce a lower specific activity probe. All probes were immediately
purified by electrophoresis on an 8 M urea 5% polyacrylamide gel, and were stored
at -200C.
7. Ribonuclease Protection Assay
Assays were carried out by using the RPA II kit (Ambion) according to the
protocol of the supplier. Briefly, total RNA (20 Itg) was hybridized simultaneously
with the CAT (2 x 105 cpm), 0-actin (1 x 105 cpm) and either OG5 or 3G3 RNA
probes (3.5 x 105 cpm) at 450 C for 14 h. Hybridization mixtures were then digested
with 1000 units/ml RNase T1 by incubating at 37oC for 30 min. Following the
simultaneous inactivation of the RNase T1 and ethanol precipitation of the protected
radiolabeled RNA probes, the protected fragments were separated on an 8 M urea 5%
polyacrylamide gel. Quantitative analysis was performed by using a Phosphorlmager
(Molecular Dynamics).
8. Calculation of Bypass Efficiencies
Bypass efficiencies of RNA polymerase II for a single representative DNA
adduct of either cis- or trans-DDP were calculated as follows. The gene inactivation
target was considered to include either the CMV promoter and transcribed strand of
the 0-gal coding sequence and SV40 splice/polyadenylation sequence (5120
nucleotides of 14976 total nucleotides in plasmid) or alternatively only the transcribed
strand of the coding and polyadenylation sequence (3936 of 14976 total nucleotides).
The DoT, or number of platinum adducts required within this putative gene
inactivation target to produce one lethal hit (reduce 0-gal enzyme activity to 37% of
the unmodified control), were calculated by multiplication of the previously
determined Do values (Table 1) by the fraction of the total plasmid that was the gene
inactivation target. All DOT values were assumed to follow a Poisson distribution.
The following polynomial equation, in which each term describes the individual
contributions of each population of adducts described by the Poisson distribution to
the total transcription blocking observed, was then solved iteratively:
0.37 = (a x Xo) + (b x X') + (c x X2) + (d x X3) + (e x X4) + (f x X5) ...
where for a given DOT value, the Poisson distribution would predict that fraction a of
the platinum modified DNA population would contain no adducts, b would contain
one adduct, c would contain two adducts, d would contain three adducts, and so on;
0.37 refers to the fraction of transcriptional activity at which DOT was determined; X
represents the bypass frequency of RNA polymerase for a single representative adduct
of either platinum isomer. This calculation of bypass efficiency was carried out
twice, where the gene inactivation target sequence was considered either to include,
or not, the promoter region of the gene; the two resulting values for bypass efficiency
represent a maximum and minimum estimation, respectively, of the actual bypass
efficiency. Bypass efficiencies were similarly calculated for the experiment where
ribonuclease protection analysis was used to monitor directly the inhibition of
transcription elongation. In this case, however, the gene inactivation target was
considered to be the 1604 nucleotide sequence flanked by the two antisense RNA
probes. Do values were determined from the curves exponentially fitted to the data.
C. Results
1. Host cell reactivation of cis- and trans-DDP damaged plasmids in HeLa cells
The relative effects of cis- and trans-DDP DNA adducts on transcription were
examined by using the host cell reactivation assay. HeLa cells were transfected with
cis- or trans-DDP damaged CMV-0-gal plasmid DNA and, after 24 h, f-gal activities
and total protein content were determined. Relative to the f-gal activity from
unmodified plasmid, which was defined as 100%, f-gal expression decreased
exponentially with increasing platinum damage (Figure 4). A reference point used for
comparison of the dose response curves is Do, or the level of DNA damage sufficient
to reduce the f-gal activity to 37% of its original value along the exponential portion
of the curve (Protic-Sabljic and Kraemer, 1985). Two-fold more trans-DDP damage
(Do = 40 adducts/genome; rb= 0.0027) than cis-DDP damage (Do = 21
adducts/genome; rb= 0.0014) was required to produce an equivalent reduction in f-
gal activity. Three testable models could explain the differential reactivation of
plasmids modified by cis- and trans-DDP: (1) translesion synthesis by RNA
polymerase may be more efficient on DNA modified by trans-DDP than cis-DDP; (2)
trans-DDP adducts may be more rapidly repaired than cis-DDP adducts; and (3) there
may be preferential formation of cis-DDP adducts compared with trans-DDP adducts
within the f-gal gene.
In order to determine whether the differential reactivation effects observed in
Figure 4 were a consequence of different distributions of cis- and trans-DDP DNA
adducts, the reactivation assay was carried out in HeLa cells using a second plasmid,
PSV2-CAT. PSV2-CAT differs from CMV-3-gal in that it contains different
potential gene-inactivating target (i.e., promoter, coding, and splice/polyadenylation
sequences) as well as non-target sequences (Figure 5). With PSV2-CAT, the Do
value for trans-DDP was 38 adducts/genome (rb= 0.0038), as compared to 19
adducts/genome for cis-DDP (rb= 0.0019). This two-fold difference in Do values was
identical to that observed in the CMV-0-gal system. These observations argued
against the possibility that the different levels of gene expression from cis- and trans-
DDP modified DNA is a consequence of different platinum levels within the
transcribed reporter gene.
2. Impact of nucleotide excision repair status on reactivation of platinated DNA
in human cell lines
In order to assess the possible contribution of excision repair to the observed
greater reactivation of trans-DDP-modified DNA, the host cell reactivation assay was
carried out in nucleotide excision repair deficient XPA and apparently normal,
consanguineous human lymphoblasts. Measurement of f-gal activity 24 h (- one cell
doubling time) after transfection of both cell lines with cis- or trans-DDP damaged
plasmid demonstrated the expected reduction in activity with increasing platinum
damage (Figure 6). XPA cells exhibited a steeper dose response than did repair
proficient cells. The four-fold differential in Do values found for XPA and normal
cells (Table 1) is comparable to differences previously observed for cis-DDP (Poll et
al., 1984; Chu and Berg, 1987) and for UV damage (Lehmann and Oomen, 1985;
Protic-Sabljic and Kraemer, 1985; Athas et al., 1991). A comparison of the two
platinum compounds in normal lymphoblasts revealed a 1.6-fold greater Do value for
trans- compared to cis-DDP, consistent with our results obtained in HeLa cells.
Experiments in XPA cells, in which platinum adducts cannot be removed by excision
repair, found an even larger differential of 2.7-fold between cis- and trans-DDP. If
excision repair were contributing to the differential reactivation of cis- and trans-DDP
damaged DNA observed in normal cells, one would have expected to find similar Do
values for cis- and trans-DDP in excision repair deficient cells.
3. Impact of nucleotide excision repair status on reactivation of platinated DNA
in rodent cell lines
Additional experiments were performed to assess whether the observed
differential effects of cis- and trans-DDP on transcription might be species or cell line
specific. CHO repair proficient AA8 cells and excision repair deficient UV20 cells
were transfected in parallel with cis- or trans-DDP damaged CMV-0-gal DNA, and
0-gal activity was measured 15 h (- 1 cell doubling time) after transfection. As shown
in Figure 7, the transcriptional activity from platinated DNAs decreased exponentially
with increasing dose. A - 3.5 fold enhanced reactivation of trans-DDP damaged
plasmid was found in either cell line (Table 1). Interestingly, Do values obtained in
AA8 cells were virtually identical to those found in UV20 cells (Table 1), suggesting
that little or no repair of either platinum isomer, within the detection limits of this
assay, had yet occurred in the repair proficient AA8 cells. It is interesting that no
repair was apparent by this assay after one doubling time in CHO cells, whereas
significant levels were observed in human lymphoblasts after 24 h, approximating one
doubling time for these cells. This distinction may reflect a less efficient or rapid
DNA nucleotide excision repair system in rodent cells as compared to human cells.
P-gal activity was next measured in either cell line 48 h after transfection. In
excision repair deficient UV20 cells, Do values found for cis- and trans-DDP at 48 h
were identical to those found at 15 h. This result illustrates the repair deficient
phenotype of UV20 cells and supports the view that excision repair is the primary
mechanism of removal of platinum DNA adducts, although the action of other repair
pathways on the platinum adducts before 15 h cannot be excluded. In contrast, in
repair proficient AA8 cells, Do values for cis- and trans-DDP increased significantly
and proportionately from 15 to 48 h, indicating excision repair of the adducts of both
isomers. A comparison at 48 h of the two isomers in repair proficient cells revealed
a 3.2-fold larger Do for trans-DDP than for cis-DDP; in the absence of repair this
difference was 4.3-fold. This trend in the changes of Do values obtained in CHO
cells at 48 h paralleled closely that observed in human cells. Taken together, our
results in CHO and human cells indicate that excision repair of trans-DDP lesions was
not contributing to the greater reactivation of trans-DDP damaged DNA in these
studies.
4. Effects of platinum DNA adducts on transcription elongation
Experiments were carried out to examine whether platinum DNA adducts were
inhibiting fl-gal gene expression by blocking RNA polymerase processivity in vivo.
Blocking of mRNA synthesis within a defined region of the 0-gal gene was measured
directly by ribonuclease protection analysis. Excision repair deficient XPA cells were
used in order to eliminate, as far as possible, any differences in excision repair as a
variable in the experiment. XPA cells were cotransfected with cis- or trans-DDP
modified CMV-0-gal and a second unmodified plasmid, pcDNA3-CAT, to control for
transfection efficiency. Total RNA was isolated four h after transfection of the cells
in further effort to ensure that the effects of transcription, and not leaky excision
repair, were being monitored. Northern analysis verified that total RNA samples
were free of contaminating plasmid DNA (data not shown). Total RNA was
hybridized simultaneously with antisense RNA probes for CAT, constitutively
expressed 0-actin, and one of two sequences within 0-gal mRNA. One 0-gal probe,
fG3, complementary to a sequence located at the immediate 3' end of 0-gal mRNA
(Figure 8A), was used to measure only full length mRNA transcript. A second
probe, fG5, was complementary to a sequence located 1604 bp upstream from the
OG3 sequence (Figure 8A). 3G5 detected full length transcripts as well as those
prematurely terminated due to the presence of platinum adducts within the 1604 bp
sequence between 3G3 and 3G5. RNAs from the same sample but hybridized with
either /G3 or /G5 were run in adjacent lanes. A representative autoradiograph is
shown in Figure 8B.
Hybridizations with 3G3 showed that amounts of full length transcript
decreased exponentially with increasing platinum modification (Figure 8B, B lanes).
Curves generated from these data exhibit a three fold differential in Do values for cis-
and trans-DDP (curves not shown), in agreement with that found in previous
experiments with XPA cells where 3-gal enzyme activity was measured.
Hybridizations with 3G5 (Figure 8B, A lanes) also showed a decrease in 3-gal mRNA
transcript with increasing number of cis-DDP adducts. By contrast, similar levels of
trans-DDP adducts had relatively little effect on mRNA levels detected by this probe.
Data obtained from these two antisense RNA probes were used to calculate the
fraction of total f-gal mRNA (3G5) that was successfully transcribed through the
1604 bp region to yield full length transcript (1G3). Studies in vitro indicate that only
platinum adducts present on the transcribed strand of DNA effectively block RNA
polymerase processivity (Corda et al., 1991). The fraction 3G3/3G5 therefore
provides a measure of the blocking effected by platinum adducts on the transcribed
strand of the 1604 bp region. Curves generated from these data (Figure 9) revealed
that 1.2 cis-DDP adducts were required in this 1604 nucleotide sequence to reduce
full length transcript to 37% of that synthesized from unmodified plasmid. At the
levels of modification examined for trans-DDP, full length transcript never fell below
56%. The slope of the dose-response curve predicts, however, that - 5 trans-DDP
adducts would be necessary to effect 37% inhibition. These results indicate that cis-
DDP DNA adducts block RNA polymerase processivity more effectively than trans-
DDP adducts in vivo by at least 4-fold.
D. Discussion
1. Differential inhibition of RNA transcription by cis- and trans-DDP
The effects of the anticancer drug cis-DDP and its geometric isomer trans-
DDP on RNA synthesis were investigated in vivo by using a nonreplicating transient
expression vector in a host cell reactivation system. Transfection of HeLa cells with
cis- or trans-DDP damaged plasmid revealed a two fold greater expression of the
template modified by trans-DDP than by cis-DDP (Figure 4,5). These data suggested
that DNA adducts of cis-DDP were more inhibitory to transcription than adducts
formed by trans-DDP. Alternatively, the possibility existed that more efficient repair
of trans-DDP adducts compared with cis-DDP adducts could have contributed to our
observations. The latter observation would be consistent with the suggestion of a
previously published report (Ciccarelli et al., 1985; Heiger-Bernays et al., 1990).
Nucleotide excision repair is believed to be the main process by which
platinum adducts are removed from DNA. More specifically, cis-DDP adducts are
known substrates for transcription-coupled excision repair (Jones et al., 1991; May et
al., 1993), of relevance in that the assay used in this study monitors adducts present
in an actively transcribed gene. Cells from patients with the autosomal recessive
disease XP belonging to complementation group A are defective for XPAC (XPA
complementing) protein, which binds cis-DDP damaged DNA and functions as a key
component in recognition of DNA damage during repair (Jones and Wood, 1993).
XPA cells are thus deficient in the incision step of excision repair (Cleaver, 1968;
Friedberg, 1985). It has been demonstrated that XPA cells are deficient in the repair
of cis-DDP (Chu and Berg, 1987; Dijt et al., 1988; Hansson et al., 1990) and trans-
DDP DNA adducts (Hansson et al., 1990), as well as in the transcription-coupled
repair of cis-DDP (Zhen et al., 1993) and UV (Evans et al., 1993) damage. Our
experiments in XPA cells (Figure 6; Table 1) showed that the differential in Do values
for trans-DDP compared to cis-DDP (2.7-fold) was enhanced relative to that found in
a consanguineous normal cell line (1.6-fold). This result suggested that preferential
excision repair of trans-DDP was not the cause of the enhanced expression found for
trans-DDP damaged DNA.
Experiments carried out in CHO excision repair deficient UV20 cells
(complementation group 1, formerly group 2) gave remarkably similar results (Figure
7; Table 1). The CHO group 1 repair defect is partially complemented by the human
ERCC1 gene (van Duin et al., 1988; Larminat and Bohr, 1994). The ERCC1 gene
product, by comparison with its homologous protein Rad 10 in S. cerevisiae (van
Duin et al., 1986), is believed to function in the 5' incision step of excision repair as
well as in mitotic recombination (Bardwell et al., 1994). This latter point is relevant
in that interstrand crosslinks may require recombinational repair for their removal
from DNA. CHO group 1 repair deficient cell lines have an increased sensitivity to
both cis- and trans-DDP (Hoy et al., 1985), are deficient in the removal of interstrand
(Meyn et al., 1982) as well as intrastrand cis-DDP cross-links (Larminat and Bohr,
1994), and have been shown to be deficient in the repair of cis-DDP adducts present
in an actively transcribed gene (Larminat and Bohr, 1994). Our experiments showed
that the differential in Do values for trans-DDP compared to cis-DDP was, again,
slightly greater in the repair deficient UV20 (4.3-fold) than in the parental AA8 (3.7-
fold) cell lines. Further, significant repair of both isomers was observed, as
operationally defined by this assay, in the time that elapsed between 15 h and 48 h
after transfection in AA8 cells. By contrast, no repair of either isomer was evident
during the same time period in the UV20 cells. The most straightforward explanation
of these data is that excision repair is the primary mechanism of platinum adduct
removal for both platinum isomers. The formal possibility exists that trans-DDP
lesions could be removed by an additional process in excision repair deficient cells;
to date, however, there is no evidence of such a process. The same differential
between cis- and trans-DDP was found at 15 h and 48 h, further supporting the view
that excision repair did not contribute to the enhanced transcriptional activity from
trans-DDP damaged templates. Taken together, the results from human and rodent
repair deficient cell lines thus suggested that cis-DDP adducts inhibited transcription
more efficiently than adducts of trans-DDP in vivo.
A statistical analysis of the data obtained in excision repair deficient cells,
assuming that repair by another putative process is negligible, allowed the calculation
of an approximate efficiency of translesion synthesis by RNA polymerase. Inhibition
of transcription by platinum adducts could be caused by the impeded translocation of
RNA polymerase II along the transcribed strand of the DNA template (Corda et al.,
1991). Gene inactivation could also be mediated at the level of initiation through the
inhibition of transcription factor binding (Mymryk et al., 1995). In this analysis the
gene inactivation target sequence within CMV-0-gal was therefore considered to
include the double stranded promoter region as well as the transcribed strand of the
coding and splice/polyadenylation sequence. This analysis revealed that, on average,
1.2 cis-DDP DNA adducts within this putative target were required to reduce 0-gal
activity by 63 % (DOT) in XPA cells. In contrast, at least 3.3 DNA adducts of trans-
DDP were necessary to produce the same level of inhibition. If gene inactivation at
the promoter was small and can be ignored, the DOT values obtained in repair deficient
cell lines can then be used to calculate an approximate bypass efficiency of RNA
polymerase for both cis- and trans-DDP. This calculation was accomplished by using
the Poisson distribution of DOT for either isomer. Inclusion of the promoter in the
target sequence that ultimately determined DOT may or may not be a valid assumption.
By carrying out calculations for both situations, however, an upper and lower limit
for the bypass rates of each isomer could be established. The bypass frequency by
RNA polymerase for a single DNA adduct of trans-DDP was determined to be in the
range of 60-76%, whereas the rate of bypass of a single cis-DDP adduct was
calculated to be between 0-17% (summarized in Table 2). The DOT for cis-DDP of - 1
indicates, assuming a Poisson distribution of adducts, that the observed gene
expression from cis-DDP damaged template originated almost entirely from a DNA
population that contained no platinum adducts within the target sequence.
The analysis detailed above relied on the assumption that adducts in the
promoter region contributed negligibly to gene inactivation in our experiments. If
adducts in the promoter region were important, then our putative bypass efficiencies
may have been underestimated. This possibility led to a direct comparison of the
relative abilities of cis- and trans-DDP DNA adducts to block transcription
elongation. RNA synthesis through a specific portion of the 0-gal coding sequence in
vivo was monitored by ribonuclease protection analysis (Figure 8A,B). Results of this
experiment revealed that 1.2 cis-DDP adducts, on average, were required in the
transcribed strand of the monitored region to inhibit transcription elongation by 63 %
(Figure 9). The slope of the dose-response curve for trans-DDP predicts that - 5
adducts would be necessary to produce equivalent inhibition. These data, obtained by
the direct examination of transcript elongation (Table 2), were consistent with those
found by measuring overall 0-gal expression, suggesting that cis-DDP adducts
mediated transcriptional inactivation in our system primarily at the level of the coding
region. The data further suggested that cis- and trans-DDP adducts block RNA
polymerase II in vivo differentially by a minimum of 4-5 fold. It is noteworthy that
the CMV promoter represents only 23% of the total gene inactivating target sequence
in CMV-fl-gal; the relative size of the promoter compared to the coding sequence,
therefore, may be the reason for the observed minimal contributions derived from
adducts within the promoter.
2. Molecular basis for transcription inhibition by platinum DNA adducts
It has long been known that DNA damage has an inhibitory effect on
transcription (Sauerbier and Hercules, 1978). Bifunctional alkylating agents such as
chlorambucil, melphalan, nitrogen mustard (Pieper et al., 1989), and sulfur mustard
(Masta et al., 1996) are known to inhibit transcription. DNA adducts formed by
acetylaminofluorene (Donahue et al., 1996) and thymine glycol, a lesion arising from
ionizing radiation and spontaneous oxidative damage, also block RNA polymerase II
in vitro (Htun and Johnston, 1992). Cyclobutane pyrimidine dimers, the predominant
DNA lesions induced by UV radiation, are strong blocks to rat RNA polymerase II
during transcription elongation when present on the transcribed strand in vitro
(Donahue et al., 1994). In vivo studies of UV damage using the host cell reactivation
assay report that 1 UV lesion in a - 2 kb target was sufficient to reduce gene
expression by 63% in XPA fibroblasts (Protic-Sabljic and Kraemer, 1985). Our
results that 1.2 cis-DDP adducts were required to effect an equivalent inhibition in
XPA lymphoblasts suggested that a single cis-DDP adduct presented an equivalent
block to transcription elongation as one pyrimidine dimer.
The results outlined in this chapter are in agreement with previous in vitro
studies examining the effects of specific DNA adducts formed by cis- and trans-DDP
on transcription elongation by purified eukaryotic RNA polymerases (summarized in
Table 3). Results of such studies show that each of the three predominant intrastrand
adducts formed by cis-DDP, including the 1,2-d(GpG), 1,2-d(ApG) and 1,3-
d(GpTpG) cross-links, as well as the interstrand cross-link at a d(GC) site, provide
absolute blocks to RNA polymerases when present on the transcribed strand (Corda et
al., 1991; Corda et al., 1993). Such adducts comprise - 97% of the total adduct
spectrum of cis-DDP (Bruhn et al., 1990). Our range of bypass rates (0-17%) for
cis-DDP in vivo are thus consistent with results from these in vitro studies. By
contrast, in vitro studies with trans-DDP have found that the intrastrand 1,3-
d(GpTpG) adduct of trans-DDP, unlike that formed by cis-DDP, does not provide an
absolute block to RNA polymerase in vitro (Corda et al., 1993). Although the trans-
DDP adduct spectrum has not been as well characterized as that of cis-DDP, the 1,3-
d(GpNpG) adduct could account for - 40% of the total adducts formed by the trans
isomer (Eastman et al., 1988). Our results (bypass efficiencies of 60-76%) thus
suggest that this lesion, and the bulk of the remaining intrastrand adducts formed by
trans-DDP, are bypassed in vivo. The trans-DDP interstrand cross-link, which blocks
transcription elongation effectively in vitro (Brabec and Leng, 1993) and represents up
to 20% of the total in vitro adduct spectrum (Eastman et al., 1988; Brabec and Leng,
1993), could be responsible for a significant portion of the - 30% blocking efficiency
observed in this work.
Why might intrastrand DNA adducts of cis-DDP be more effective blocks to
RNA polymerase processivity than those of trans-DDP? An explanation may lie in
the structural differences between the intrastrand adducts of the two compounds. The
1,2-d(GpG) cis-DDP adduct induces a directed bend of 340 towards the major groove
(Bellon and Lippard, 1990; Yang et al., 1995; Takahara et al., 1995), and unwinds
the helix by 13' (Bellon et al., 1991); both the 1,2-d(ApG) and 1,3-d(GpTpG) cis-
DDP adducts induce similar DNA bending (34°) and unwinding (-130 and -23o,
respectively) (Bellon and Lippard, 1990; Bellon et al., 1991). By contrast, the 1,3-
d(GpTpG) trans-DDP adduct imparts a nondirected bend to the DNA helix, forming a
hinge joint (Bellon and Lippard, 1990; Bellon et al., 1991). It is possible that
increased flexibility as a structural element of platinum-DNA adducts may allow for
more facile translesion synthesis through the site of damage. The recent crystal
structure of the 1,2-d(GpG) adduct in a duplex dodecamer reveals that the DNA helix
surrounding the lesion undergoes an abrupt change from B-type to an A-type DNA
architecture (Takahara et al., 1995). If this unique structure occurs in vivo, it is
possible that the transcription complex senses and is halted by such a change in DNA
structure. Alternatively, it is possible that monofunctional trans-DDP adducts
transiently formed during the described rearrangements of the 1,3-d(GpNpG) trans-
DDP adduct to a 1,4-d(CpGpCpG) adduct (Comess et al., 1990) and to an interstrand
crosslink (Dalbies et al., 1994) provide greater opportunity for bypass by the
polymerase.
It is additionally interesting that cis- and trans-DDP adducts differentially
affected the translocation of RNA polymerases, while no significant differences are
observed in blocking of DNA polymerases. It is reasonable to speculate that enzyme
fidelity may be less crucial for RNA polymerase as compared to DNA polymerase.
An error that is incorporated during DNA replication would have potentially
devastating long-term consequences, whereas reduction in transcriptional fidelity
would be expected to be more tolerable. Upon arrest of RNA polymerase II at
transcriptional pause sites, it is known that the transcription factor SII can induce
nascent transcript cleavage and, in some cases, shortening of the transcript at the 3'
end. These events apparently give the polymerase the opportunity to reelongate the
nascent RNA chain through the pause site (Reines, 1994). In this way the eukaryotic
transcription complex appears to possess a mechanism that increases the number of
chances a polymerase molecule has of bypassing the block.
3. Implications regarding the relative repair of cis- and trans-DDP adducts
Differential transcriptional inhibition as demonstrated in this report is one of
several effects that may act in concert to bring about the different toxicities of cis-
and trans-DDP. For example, incubation of DNA templates modified by cis- or
trans-DDP with mammalian cell free extracts results in enhanced repair of trans-DDP
damaged templates over those modified with cis-DDP, suggesting that preferential
repair may explain, at least in part, the lower toxicity of trans-DDP (Hansson and
Wood, 1989; Heiger-Bernays et al., 1990). Studies in vivo, however, have yielded
conflicting views that may be attributable to technical differences in experimental
design' (Ciccarelli et al., 1985; Roberts and Friedlos, 1987). Interestingly, the results
of the present study indicate that, in the system used, excision repair of cis- and
trans-DDP adducts occurs to an equal extent. This conclusion is supported by the
relatively proportionate increase in Do values for cis- and trans-DDP when determined
in excision repair deficient and then repair proficient cell lines, both of human and
rodent origin (Table 1).
The apparent discrepancy between the similar repair of cis- and trans-DDP
observed in the present study and the evidence for preferential repair of trans-DDP in
some of the literature can be explained in several ways. First, one aforementioned
possibility is that the trans isomer is repaired by a pathway in addition to nucleotide
excision repair. Second, the possibility exists that a population of trans-DDP adducts
may be completely uninhibitory to transcription, and therefore would be undetectable
by the host cell reactivation assay. If this adduct population were repaired
1 See section B, part 3 of literature survey for further discussion on this point.
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preferentially, then this repair would go undetected as well. These non-inhibitory
trans-DDP lesions could include specific intrastrand crosslinks, monofunctional
adducts, or perhaps transient monofunctional adducts that exist during the described
rearrangement from 1,3-intrastrand to 1,4-intrastrand crosslinks of trans-DDP
(Comess et al., 1990). It should be noted, however, that under the conditions of our
platination reactions, few monofunctional adducts should persist (Bancroft et al.,
1990).
Another possible explanation for the apparently equal repair of cis- and trans-
DDP in the present study involves the fact that cellular DNA repair is heterogeneous.
DNA repair is more efficient in the transcribed strand of expressed genes compared to
the nontranscribed strand or unexpressed DNA sequences (Hanawalt, 1994). Models
for this phenomenon depict RNA polymerase, stalled at a DNA lesion, facilitating the
direction of repair to the transcribed strand of the gene. On this basis it is speculated
that strand-specific repair may be related to the degree of transcriptional blocking, or
to the degree of chromatin distortion, invoked by the lesion (May et al., 1993). If
this view is valid, then a body of evidence (Corda et al., 1993; Mymryk et al., 1995;
Mello et al., 1995) suggests that cis-DDP may be a better substrate for transcription-
coupled repair than trans-DDP. cis-DDP adducts are known substrates for
transcription-coupled repair both in human (Evans et al., 1993) and rodent cells
(Jones et al., 1991; May et al., 1993). The host cell reactivation system used in the
present work detects repair of transcription-blocking adducts in the transcribed strand
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of the active f-gal gene, and therefore it is likely that this system specifically
monitors transcription-coupled strand-specific repair. Previous studies that suggested
preferential repair of trans-DDP were monitoring overall genome repair (Ciccarelli et
al., 1985) or repair by cell extracts of unexpressed DNA sequences (Heiger-Bernays
et al., 1990). Thus, although trans-DDP may in fact be preferentially repaired in the
overall genome, transcription-coupled repair of the transcription blocking cis-DDP
adducts on the transcribed strand of the active f-gal gene may be compensating for
that preferential repair in our system. In this context it should be noted that neither
the XPA nor the UV20 repair deficient phenotype used in these studies demonstrate
transcription-coupled repair of UV or cis-DDP damage (Zhen et al., 1993; Evans et
al., 1993; Larminat and Bohr, 1994), and therefore transcription-coupled repair could
not have influenced the difference in gene inactivation by cis- and trans-DDP found in
these cell lines.
4. Transcription inhibition as a mediator of cisplatin cytotoxicity
The results outlined in this chapter are consistent with the view that inhibition
of transcription may play a role in the cytotoxicity of cis-DDP. With regard
specifically to the antitumor activity of cis-DDP, RNA synthesis is more critical for a
rapidly dividing tumor cell than for a stationary cell (Mauck and Green, 1973).
Sorenson and colleagues have shown that cis-DDP induced cell-cycle arrest in the G2
phase and that the arrested cells proceeded either to recover or, at higher cisplatin
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doses, to die via the apoptotic pathway (Sorenson and Eastman, 1988a; Sorenson et
al., 1990). Numerous studies have subsequently demonstrated G2 cell-cycle arrest in
response to cisplatin treatment (Piacentini et al., 1993; Evans and Dive, 1993;
Shinomiya et al., 1994). Sorenson and colleagues proposed that platinum-DNA
adducts may trigger apoptosis through a general disruption of gene expression, or by
specific inhibition of a gene necessary for mitosis (Sorenson and Eastman, 1988b).
Studies testing this hypothesis have yet to be described in the literature.
Supporting the notion that inhibition of gene transcription may be a trigger for
apoptosis are results of a recent study examining induction of apoptosis by UV
damage. Ljungman et al. found that Cockayne's syndrome cells, which are
specifically defective in the specialized transcription-coupled repair pathway but are
proficient for overall genomic repair, undergo UV induced apoptosis at much lower
doses of UV light than normal cells. A comparison of normal and XPC cells, the
latter of which are proficient in transcription-coupled repair but are defective in
genomic repair, showed that they were induced to undergo apoptosis at identical doses
of UV light (Ljungman and Zhang, 1996). Induction of apoptosis in this panel of cell
lines correlates with induction of p53 and the inhibition of total and poly(A) mRNA
synthesis. These results imply that it is not the number of UV lesions in bulk DNA,
but rather the presence and persistence of UV lesions in the transcribed strand of
actively transcribed genes, that are critical for induction of apoptosis by UV damage.
The authors propose that blocking of RNA polymerase by UV lesions elicits a signal
102
that, through a cascade of events involving induction of p53, triggers execution of the
apoptotic pathway. Given that UV damage and cisplatin are similarly effective at
inhibiting RNA polymerase in vivo (1849 Protic-Sabljic 1985; this work) and in vitro
(842 Selby 1990; 1162,1837), these recent findings support Sorenson and Eastman's
original hypothesis (Sorenson and Eastman, 1988b) that blocking of RNA
transcription by cisplatin may provide a trigger for apoptosis. If inhibition of RNA
transcription does play a role in cisplatin-induced apoptosis, the present studies
suggest that trans-DDP would be much less likely to trigger this pathway.
E. Conclusions and Future Experiments
The focus of the work summarized in this chapter was to compare directly the
effects of DNA adducts formed by cisplatin and trans-DDP on RNA synthesis in
mammalian cells. The results demonstrate that both platinum complexes are capable
of inhibiting transcription in vivo, but that DNA adducts of cis-DDP, on average, are
a minimum of 4-5-fold more efficient at blocking transcription elongation by RNA
polymerase II in vivo than those of trans-DDP. The bypass efficiency of RNA
polymerase II for a single DNA adduct of trans-DDP was calculated to be 60-76%,
whereas the rate of bypass of a single cis-DDP adduct was found to be 0-17%. These
results suggest that inhibition of transcription may contribute to the significantly
greater cytotoxicity of cisplatin compared with its therapeutically ineffective trans
isomer.
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The following are suggestions for future studies:
1. Using the same ribonuclease protection assay system used in the present work, an
additional antisense RNA probe complementary to the sequence at the immediate 5'
end of the f-gal mRNA could be designed. This probe would detect differences
specifically in nascent initiated transcripts, and thus assess the relative ability of cis-
and trans-DDP to inhibit initiation from the CMV promoter.
2. Transient expression vectors containing single site-specific platinum adducts
positioned either in the promoter or the gene coding region could be constructed.
These plasmids could then be transfected into cells and the ribonuclease protection
assay system developed in this work could be used to examine directly the abilities of
individual site-specific DNA adducts of cisplatin and trans-DDP to block RNA
polymerase II elongation, and to block initiation at the site of the promoter, in vivo.
3. To date, examinations of the effects of platinum DNA adducts on transcription in
vitro have used E. coli RNA polymerase or the eukaryotic wheat germ RNA
polymerase. Recent studies have described a system using rat RNA polymerase II
and in which the effects of SII on the ability of the arrested polymerase to bypass a
lesion or to carry out nascent transcript cleavage, as well as the stability of the
arrested polymerase complex, could be assessed (Donahue et al., 1994). It would be
interesting to examine and compare the individual adducts of cis- and trans-DDP in
this system.
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4. The question of whether inhibition of gene transcription by cisplatin is critical for
cisplatin-induced apoptosis could be tested by comparing the induction of apoptosis by
cisplatin in normal repair proficient cells, XPA cells (completely deficient in excision
repair), XPC cells (deficient in overall genomic repair) and CS cells of
complementation groups A or B (deficient in transcription-coupled repair). If
inhibition of transcription plays a role in triggering apoptosis, CSA/B cells would be
expected to be more susceptible to cisplatin-induced apoptosis than both normal and
XPC cells.
5. The question of whether the host cell reactivation assay reflects overall genome
repair or transcription-coupled repair of cisplatin damage could be examined by
comparing the reactivation of cisplatin modified reporter genes in normal, XPA, XPC
and CSA/B cell lines. If transcription-coupled repair of cisplatin damage is primarily
monitored, reactivation of cisplatin modified plasmid should be relatively similar in
normal and XPC cells, while reactivation in XPA and CSA/B would likewise be
similar. Any differences in reactivation observed between XPA and XPC cells would
reflect the action of transcription-coupled repair on the plasmid DNA.
6. The experimental system described here using RNase protection to map RNA
polymerase arrest sites could be used to assess the transcriptional effects of many
other DNA damaging agents.
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Figure 4: Dose-dependent decrease in 3-gal gene expression in HeLa cells transfected
with either cis-DDP- or trans-DDP-damaged CMV-0-gal DNA. 3-gal activity in cell
lysates was normalized for protein content and is expressed as a percent of that found
in lysates from cells transfected with unmodified plasmid. Each point represents the
mean of values obtained from duplicate transfections of one representative
experiment. The relative standard deviation between experiments for the
determination of percent 1-gal activity was typically ± 10%.
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Figure 5: Dose-dependent decrease in CAT gene expression in HeLa cells transfected
with either cis-DDP or trans-DDP-damaged PSV2-CAT DNA. Amount of CAT
protein in cell lysates was normalized for total protein content and is expressed as a
percent of that found in lysates from cells transfected with unmodified plasmid. Each
point represents the mean of values obtained from duplicate transfections of one
experiment.
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Figure 6: Dose-dependent decrease in 1-gal gene expression in repair deficient XPA
(top panel) and consanguineous apparently normal (bottom panel) lymphoblastoid cell
lines transfected with either cis-DDP- or trans-DDP-damaged CMV-0-gal DNA. 0-
Gal activity in cell lysates was normalized for protein content and is expressed as a
percent of that found in lysates from cells transfected with unmodified plasmid. Each
point represents the mean of values obtained from duplicate transfections of one
representative experiment. The relative standard deviation between experiments for
the determination of percent 3-gal activity was typically ± 10%.
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Figure 7: Dose-dependent decrease in 0-gal gene expression in repair deficient
(UV20, left panels) and repair proficient (AA8, right panels) CHO cell lines that had
been transfected either 15 h (top panels) or 48 h (bottom panels) earlier with either
cis-DDP- or trans-DDP-damaged CMV-0-gal DNA. f-Gal activity in cell lysates was
normalized for protein content and is expressed as a percent of that found in lysates
from cells transfected with unmodified plasmid. Each point represents the mean of
values obtained from duplicate transfections of one representative experiment. The
relative standard deviation between experiments for the determination of percent 0-gal
activity was typically 10%.
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Table 1: Transcriptional inactivation (Do) by cis- and trans-diamminedichloroplatinum(II)
adducts in CMV-0-gal genomes: Comparison of repair deficient and repair proficient cell
linesa
Do
Platinum Derivative: cis-DDP trans-DDP
DNA Repair Status: XPA Normal XPA Normal
24 h 3.6b  12.4 9.7 21.0
DNA Repair Status: UV20 AA8 UV20 AA8
15 h 3.5c 3.6c 12.4 d  13.5 d
48 h 3.2e 11.0 c  13.7e 35.0 c
" Do values are the level of platinum compound in adducts per genome required to reduce expression of the P-
galactosidase gene of CMV-P-gal to 37% of that of an unmodified control. DO values were determined as
described in materials and methods. Do values can be converted to rb by dividing by 14,660, the total number of
nucleotides in the genome. Human lymphoblastoid lines were compared from an XP-A patient and her
apparently unaffected brother at 24 h after transfection. CHO repair deficient UV20 cells were compared with
parental repair proficient AA8 cells at both 15 h and 48 h after transfection.
h Values represent the mean of Do values obtained from three separate experiments that together utilized two
batches of independently platinated DNAs. The relative standard deviations for percent P3-galactosidase activity
between experiments were typically ±10%. Typical data of one experiment are shown in Figure 6.
c Values represent the Do from one experiment.
d Values represent the mean of Do values obtained from two experiments. The relative standard deviations for
percent 3-galactosidase activity between experiments were typically ±10%. Typical data of
one experiment are shown in Figure 7.
Same as in , except that the values represent the mean of Do values obtained from three experiments.
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Figure 8: Blocking of RNA polymerase by platinum adducts was examined directly
by ribonuclease protection. (A) Location of two antisense RNA probes that were used
to analyze transcription blocking within a 1604 bp sequence of the P-gal coding
region. The probes PG5 and PG3 produced protected fragments of 301 and 215
nucleotides, respectively. (B) Total RNA was isolated from XPA cells that had been
cotransfected previously with a cis- or trans-DDP damaged CMV-P-gal plasmid and a
second unmodified vector pcDNA3-CAT. Ribonuclease protection assays on total
RNA were carried out using antisense RNA probes for each of CAT, P-actin and P-gal
as described in materials and methods. The RNA probe used for P-gal was either 3G5
(A lanes) or PG3 (B lanes).
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Figure 9: Quantitative analysis of ribonuclease protection assay presented in Figure 8.
Levels of CAT, p-actin and P-gal mRNA protected fragments were quantitated by
PhosphorImaging. The PhosphorImaging intensity of the RNase-resistant portion of
each probe was normalized by correcting for the number of radioactive nucleotides.
The level of P-gal mRNA in each lane was additionally normalized to the level of
CAT mRNA in order to control for variations in transfection efficiency. Bands
corresponding to p-actin demonstrate that equivalent amounts of total RNA were used
for each lane. The fraction of 1-gal mRNA successfully transcribed through the 1604
bp region to reach full length was calculated by the fraction of the normalized values
PG3/PG5. This fraction is expressed as a percent of that determined for the
unmodified plasmid. Percentages are presented as a function of the number of adducts
present, on average, within the 1604 nucleotide sequence.
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Table 2: Bypass efficiency of RNA polymerase II for a single representative
DNA adduct formed by cis- or trans-diamminedichloroplatinum(II)
Pt Derivative cis-DDP trans-DDP
Human XPA" 0-17% 60-70%
CHO-UV20" 0-16% 69-76%
Human XPAb 16% ND
a RNA polymerase bypass efficiencies were determined from data obtained in transient
expression assays. Bypass efficiencies were calculated using DoT values (multiplication of Do
values summarized in Table 1 by the fraction of the total DNA genome that was the gene
inactivation target) as described in Materials and Methods. This calculation of bypass
efficiency was carried out twice, where the gene inactivation target sequence was considered to
either include, or not, the promoter region of the gene; the two resulting values for bypass
efficiency are presented as a maximum and minimum estimation, respectively, of the actual
bypass efficiency.
b Bypass efficiencies were calculated using DoT values obtained in experiments analyzing
transcription blocking by using the ribonuclease protection assay (Figure 8A,B). The gene
inactivation target was here considered to be the 1604 nucleotide sequence monitored in the
experiment. The number of platinum adducts required within the 1604 nucleotide sequence to
allow only 37% full length transcript (DOT) was obtained from the curves exponentially fitted to
the data (Figure 9).
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Table 3: Comparison of RNA polymerase II bypass efficiencies for cis- and trans-DDP DNA adducts
determined in vivo with transcription blocking of RNA polymerases by individual platinum adducts in vitro
cis-DDP trans-DDP
Percentage Inhibition Bypass efficiency Percentage Inhibition Bypass efficiency
of total in vitro' of RNA pol II of total in vitro' of RNA pol II
adducts in vivo adducts in vivo
Interstrand -2% + -I20% +
Intrastrand
GG 65% + -- 0-16% NA2  NA - 60-76%
AG 25% + NA NA
GNG 8% + -~40%
'Corda, Y., et al. (1991) Biochemistry 30, 222.
Corda, Y., et al. (1993) Biochemistry 32, 8582.
Brabec, V., and Leng, M. (1993) Proc. Natl. Acad. Sci. 90, 5345.
2NA, not applicable
IV. THE MISMATCH REPAIR PROTEIN hMSH2 BINDS SELECTIVELY
TO DNA ADDUCTS OF CISPLATIN
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A. Introduction
The goal of the work presented in this chapter was to evaluate a potential role
for the human mismatch repair recognition protein hMSH2 in the mechanism of action
of cisplatin. The rationale for this investigation stems from several independent
observations made in the literature with respect to mismatch repair: 1) Mismatch repair
activity is implicated in the toxic effects of cisplatin in E. coli; 2) MSH2 proteins
recognize DNA structures similar to those for which HMG-box proteins display
affinity; 3) hMSH2 mRNA is reported to be present at elevated levels in testicular
tissue, the tissue in which tumors are best treated by cisplatin. These observations
raised the question of whether mismatch repair proteins might physically interact with
cisplatin DNA adducts and, in so doing, play a role in the cytotoxicity and antitumor
activities of cisplatin in human cells. The work discussed in this chapter examines the
interaction of purified recombinant hMSH2 with DNA globally modified by cisplatin
and various other cisplatin analogs by both southwestern blot analysis and the
electrophoretic gel mobility shift assay. The binding of hMSH2 to DNA containing a
single site-specific 1,2-intrastrand d(GpG) cisplatin adduct was also examined.
Additionally, the relative expression levels of hMSH2 protein in a panel of human
tissues were examined by western analysis. The results support the view that
mismatch repair may play a role in sensitization of human cells to an important
anticancer drug.
122
B. Materials and Methods
1. Proteins and antibodies
Purified recombinant hMSH2 was provided by S. Acharya and R. Fishel
(Thomas Jefferson University, Philadelphia), and was overexpressed and purified as
described (Mello et al., 1996). Mouse monoclonal antibodies to hMSH2 and to ca-
tubulin were purchased from Oncogene Sciences. Goat anti mouse antibody
conjugated to horseradish peroxidase was purchased from Santa Cruz Biotechnology,
Inc. and the chemiluminescent substrate was purchased from Amersham.
2. Preparation of platinum-modified DNA probes
cis-DDP, trans-DDP, [Pt(en)C12], and [Pt(dien)Cl]Cl were prepared as described
(Watt and Cude, 1968; Dhara, 1970; Lippard et al., 1983). Restriction enzyme
digestion of pSTR3 with ClaI and EcoRV yielded 162-bp and 4205-bp restriction
fragments. Platination reactions of the restriction fragments were carried out in 3 mM
NaCl, 1 mM Na2HPO 4 (pH 7.4) with 100 [tg/ml DNA and appropriate platinum
compound/DNA molar ratios by incubating at 370C for 16 h. Unreacted platinum
compound was removed by dialysis (24 h) against 10 mM Tris-HCI (pH 8.0), 1 mM
EDTA (TE). Levels of platinum modification were determined by flameless atomic
absorption spectroscopy on a Varian AA1475 instrument equipped with a GTA95
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graphite furnace. The rb value determined for DNA modified with [Pt(dien)Cl]Cl was
approximate. The 162-bp DNA probes were radiolabeled with [cC- 32 P]dCTP (6000
Ci/mmol, New England Nuclear), purified from the 4205-bp restriction fragment on
native 5% polyacrylamide gels, and resuspended in TE to 5000-10000 cpm/pl1.
A 100-bp DNA probe containing a single, centrally located cis-
[Pt(NH 3)2 {d(GpG)-N7(1),N7(2) }] intrastrand crosslink and the analogous unmodified
control were constructed as previously described (Pil and Lippard, 1992), with minor
modifications. The six deoxyoligonucleotides used in the construction were as
follows: A: 5'-GAG ATC GAT GGA CTA GCC AGC TGC CTT GAT ATC ACG
TCA G; B: 5'-TGA TAT CAA GGC AGC TGG CTA GTC CAT CGA TCT C; C:
5'-TCG ACT GAG AAG AGA CCA GAA GGA GAC TGA CG; D: 5'-AGT ACC
CGG GTA GTC AAC AGC TGG AGC GAT ATC A; E: 5'-AGT CGA TGA TAT
CGC TCC AGC TGT TGA CTA CCC GGG TAC T; GG20: 5'-TCT CCT TCT
GGT CTC TTC TC. Deoxyoligonucleotides were purified by polyacrylamide gel
electrophoresis. The central 20-base oligonucleotide, Pt-GG20: 5'-TCT CCT TCT
G*G*T CTC TTC TC, where the asterisks denote the cis-[Pt(NH3)2{d(GpG)-
N7(1),N7(2)}] crosslink, was prepared by reacting 250 pM GG20 deoxyoligonucleotide
with 1.4 molar excess of cisplatin in a reaction containing 3 mM NaCl, 1 mM
Na2HPO4 (pH 7.4) and incubating at 370 C for 20 h. Pt-GG20 was resolved from
unreacted deoxyoligonucleotide on a 7 M urea, 20% polyacrylamide gel. The GG-20
control oligonucleotide was carried through these same steps except without cisplatin
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in the reactions. The presence of a platinum adduct in Pt-GG20 was demonstrated by
complete cyanide reversal to an unmodified state. The presence of a bifunctional
platinum adduct was confirmed by determining the molecular mass of Pt-GG20 by
electrospray mass spectrometry (calculated molecular mass = 6181, observed molecular
mass = 6178).
Oligonucleotides B, C, D, GG20 and Pt-GG20 were 5'-phosphorylated with
ATP and T4 polynucleotide kinase. Complementary strands were individually
annealed at 1:1 molar ratios (1200 pmol A and B; 1200 pmol D and E; 600 pmol C
and GG20; 600 pmol C and Pt-GG20) by heating to 900C and then cooling to room
temperature over 5 h. The DNA duplexes were then mixed in four separate 300 pmol
reactions, two containing the platinated Pt-GG20 duplex and two the control GG20
duplex, in 200 p1 total volume containing 5 ptl ligase and incubated for 12 h at 160C.
Ligated material was phenol-chloroform extracted, ethanol precipitated, resuspended in
IX TE and passed over a Sephadex G-25 QuickSpin (Boehringer Mannheim) column.
Full length 100-mers were purified from unligated material by electrophoresis on a 7
M urea, 8% polyacrylamide gel, eluted in IX TE, ethanol precipitated and resuspended
in IX TE. Following reannealing of the two complementary strands by the same
protocol as above, the 100-bp duplex DNA was purified from contaminating single-
stranded DNA on a native 12% polyacrylamide electrophoresis gel. Duplex DNA was
eluted in IX TE, ethanol precipitated, air dried and resuspended in IX TE. Final
yields were typically 25-42%. Probes were radiolabeled with [y- 32 P]ATP (6000
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Ci/mmol, New England Nuclear), passed over a Sephadex G-50 Quick Spin column,
and stored at -20'C.
3. Binding assays
Binding assays typically contained radiolabeled 162-bp DNA probes (present at
100-200 pM, 5000-10000 cpm) either unmodified or modified with platinum
compounds, and purified hMSH2 present at 0-500 nM. Binding reactions were carried
out in 15 p1 reactions containing 25 mM potassium phosphate (pH 7.5), 25 mM NaC1,
0.5 mM dithiothreitol, 0.05 mM EDTA, 50 ýpg/ml BSA, 5% glycerol, and 50 ng of
nonspecific chicken erythrocyte competitor DNA. Binding was performed at 350C for
10 min. Samples were then loaded onto 4% (29:1; acrylamide:bis) native
polyacrylamide gels containing IX TBE (90 mM Tris (pH 8.0), 2.0 mM EDTA, 90
mM boric acid) and 5% glycerol, and electrophoresed at 40C in IX TBE at 25 mA for
two h. Binding assays with 100-bp probes (100 pM, 8000 cpm) were similarly
conducted except that 10 ng of nonspecific chicken erythrocyte competitor DNA was
present in the reactions. Amounts of bound and unbound radiolabeled probe were
determined by quantitative analysis of dried gels using a Molecular Dynamics
PhosphorImager. The Kd(app) was determined by a nonlinear least squares fitting of the
binding data to the standard Hill equation (Creighton, 1993).
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4. Competition assays
Competition assays were carried out by titrating increasing amounts of
nonradiolabeled competitor DNA into binding reactions that contained constant
amounts of both hMSH2 (present at 130 nM) and 32 P-labeled 162-bp cisplatin-
modified (rb = 0.018) DNA probe (present at 150 pM). Nonradiolabeled competitor
DNA was pBR322 that was either unmodified (control) or modified with cisplatin (rb =
0.043).
5. Western blot analysis
Nuclear and whole cell extracts from HeLa cells were prepared as described
(Dignam et al., 1983). Whole cell extracts of the human embryonic carcinoma cell
line N-Tera 2.D1 (Andrews et al., 1984) were kindly provided by E. Trimmer.
Preprepared protein extracts from adult human tissues were obtained from Clontech.
For Western blot analysis of hMSH2, 400 jlg of protein from human tissues, 75 jig of
protein from HeLa nuclear extract, and 10 ng of purified hMSH2 were resolved on an
8% SDS-polyacrylamide gel and electroblotted to nitrocellulose. For Western blot
analysis of a-tubulin, 100 jtg of protein from human tissues and 75 jig of nuclear
HeLa extract were used. Blots were preincubated in 10 mM Tris, 150 mM NaC1,
0.05% Tween (IX TTBS) containing 5% milk for 30 min and washed once with 1X
TTBS. The blots were incubated with a primary mouse monoclonal antibody either to
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hMSH2 (Oncogene Sciences) or to a-tubulin (Oncogene Sciences) at concentrations of
0.8 jpg/ml (1:133 dilution) and 0.1 jpg/ml (1:1000 dilution), respectively, in IX TTBS
containing 1% milk for 2 h. Following 3 x 20 min washes with IX TTBS, blots were
incubated with a horseradish peroxidase-labeled secondary antibody (Santa Cruz
Biotechnology, Inc.) at a 1:2000 dilution for 30 min. Blots were then subjected to 3 x
15 min washes with IX TTBS and 1 x 3 min wash with 10 mM Tris, 150 mM NaC1.
Antigen specific signals were visualized by using enhanced chemiluminescence
(Amersham) according to the manufacturer's recommendations and blots immediately
exposed to film for 10-30 min. Autoradiograms of Western blots were scanned using
a Hewlett Packard Scanjet IIp and scanned images were analyzed by using the NIH
Image 1.6 program. Relative intensities of hMSH2 signal were determined after
normalization to the band for a-tubulin.
6. Southwestern analysis
Protein samples (75 [tg of HeLa whole cell extract, nuclear extract, and N-Tera
2.D1 whole cell extract) were resolved on 5-15% gradient SDS/polyacrylamide gels
and transferred to nitrocellulose membranes. The air-dried membranes were processed
as previously described (Toney et al., 1989) with minor modifications. In the probing
step, the labeled DNA was present at -5 x 104 cpm/ml, and the nonspecific competitor
poly[d(I.C)-d(I.C)] was at 5 jtg/ml. The DNA probe was modified with cisplatin (rb
0.037), trans-DDP (rb = 0.052) or was an unmodified control. Protein-DNA
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complexes were detected by using a Molecular Dynamics PhosphorImager. For the
accompanying Western analysis, the filter was probed with a mouse monoclonal
antibody to hMSH2 (Oncogene Sciences) at 0.2 [gg/ml (1:500 dilution), and antibody
binding was visualized by using a chemiluminescent detection system (Bio-Rad).
C. Results
1. Examination of hMSH2 binding to cisplatin modified DNA by Southwestern
analysis
Previous studies of interactions between cisplatin modified DNA and proteins
present in HeLa cell-free extracts by Southwestern analysis revealed species of 97, 94
and 28 kDa (Toney et al., 1989; Treiber et al., 1994). These observations led to the
eventual demonstration that the HMG domain containing proteins hUBF (97/94 kDa)
and HMG-1 (28 kDa) bind specifically to cisplatin DNA adducts (Pil and Lippard,
1992; Treiber et al., 1994). In these same studies, a 105 kDa band was also detected
with cisplatin modified probes, and to a much lesser extent with unmodified or trans-
DDP modified probes (Treiber et al., 1994). The molecular weight of hMSH2, 105
kDa, suggested that this mismatch repair protein could be the 105 kDa species detected
in the prior studies. Parallel Southwestern and Western blots of proteins present in
HeLa nuclear and whole cell extracts were carried out in an effort to determine
whether the 105 kDa species was hMSH2 (Figure 10). Whole cell extracts of the
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human carcinoma cell line N-Tera 2.D1, which was derived from an embryonal
carcinoma testicular tumor (Andrews et al., 1984), were also examined in this
experiment for the presence and/or levels of hMSH2; embryonal carcinoma testicular
tumor cell lines have been shown to be extremely sensitive to cisplatin toxicity
(Oosterhuis et al., 1984).
One single band corresponding to hMSH2, which migrated as 107 kDa,
appeared in the Western blot (Figure 10b). Approximately equal levels of hMSH2
were detected in the HeLa and embryonal carcinoma cell extracts. In the
Southwestern blots, only two bands were detected in the 100 kDa region (Figure 10a).
The more intense of these two bands appeared to correspond to the prior "105 kDa"
band in that it was also detected by unmodified and trans-DDP modified probes; in my
experiments, however, this species ran as 98 kDa. The resolution achieved apparently
did not allow detection of discrete 97 and 94 kDa species corresponding to hUBF,
which likely are comigrating with this intense band. A second, fainter and slower
migrating species, which ran in my experiments as 107 kDa, was specifically detected
by cisplatin modified DNA and appeared to migrate at the same position as hMSH2 in
the Western blot. It is not clear whether this band was observed in prior studies.
Although this upper band appeared to comigrate with hMSH2 in the Western blot, this
in no way proves the identity of the species. In order to identify this species
definitively as hMSH2, similar experiments would need to be carried out in which
both purified hMSH2 protein and extracts from cells deficient in hMSH2 were
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included in the Southwestern and Western analysis. Greater resolution in the 100 kDa
region of the blot would also be required. These points notwithstanding, we were
encouraged to look further at the possibility that hMSH2 might be a platinum adduct
binding protein.
2. hMSH2 binds selectively to DNA modified by therapeutically active platinum
compounds
In order to test the hypothesis that hMSH2 might recognize cisplatin-modified
DNA, purified hMSH2 was used in an electrophoretic mobility shift assay with DNA
globally modified by cisplatin and cisplatin analogs (Figure 11). Binding of hMSH2
protein to a radiolabeled 162-bp DNA probe containing cisplatin DNA adducts was
readily observed by the retarded migration of the radiolabeled probe through the gel
(Figure 12, lane 4). Under identical conditions the protein did not cause a shift of
unmodified 162-bp probe (Figure 12, lane 2). Unlabeled nonspecific competitor DNA
(chicken erythrocyte DNA of homogeneous length) was required in the binding
reactions in order to observe discrete bands. When the synthetic polymer poly[d(I*C)-
d(I*C)] was present as the nonspecific competitor DNA in these reactions, shifted
bands were more diffuse and relatively little difference in binding was observed
between the platinated and unmodified DNA probes. Although the cause of this
behavior is unclear, it is possible that the poly[d(I*C)-d(I*C)] forms looped DNA
structures that are attractive to hMSH2, and thus compete for specific binding to the
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platinated probe.
A hallmark of the interaction of HMG box proteins with platinum damage is
the observed selectivity for DNA adducts of therapeutically active platinum compounds
(Toney et al., 1989; Pil and Lippard, 1992). It is this specificity that has suggested a
role for HMG box proteins in the mechanism of action of cisplatin. In order to
determine if hMSH2, which does not contain an HMG box, might display similar
selectivity, the interaction of hMSH2 with DNA modified by various cisplatin analogs
(Figure 11) was examined. hMSH2 bound to DNA modified by the therapeutically
active platinum analog [Pt(en)Cl 2] (en, ethylenediamine) (EN; Figure 12, lane 8),
although to a lesser extent than that observed for cisplatin modified DNA. By
contrast, hMSH2 displayed no affinity for DNA containing adducts of the inactive
platinum complexes trans-DDP and [Pt(dien)Cl] ÷ (dien, diethylenetriamine) (DIEN;
Figure 12, lanes 6 and 10, respectively).
Cisplatin and [Pt(en)C12] differ from the two clinically inactive compounds in
that the chloride ligands possess a cis geometry, enabling the formation of 1,2-
intrastrand crosslinks at adjacent nucleotides. These crosslinks, formed at GG and AG
sites, comprise greater than 90% of all adducts formed by cisplatin (Eastman, 1983;
Fichtinger-Schepman et al., 1985). The observed hMSH2 binding results suggest that
this protein may recognize either or both of the 1,2-intrastrand platinum adducts. Less
binding was observed to DNA modified with [Pt(en)C12] compared to that with
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cisplatin. This result is interesting in that the two platinum complexes are believed to
form the same spectrum of adducts (Eastman, 1983). This differential may be due in
part to a slight difference in modification level of the two DNA probes (rb = 0.018 vs.
0.012 for cisplatin and [Pt(en)C12], respectively). These results may also indicate that
substitution of the two ammine groups of cisplatin with a bidentate ligand
(ethylenediamine) negatively affects hMSH2-cisplatin adduct interactions.
3. Characterization of the interaction between hMSH2 and cisplatin modified
DNA
In order to characterize further the nature of the interaction between hMSH2
and cisplatin modified DNA, hMSH2 protein was titrated into binding reactions
containing a constant concentration of cisplatin-modified DNA probe. At hMSH2
concentrations approximating half-maximal binding, two distinct bands were
consistently observed (Figure 13A). The addition of increasing amounts of protein
caused the complex to be increasingly retarded through the gel, presumably because
multiple proteins bound to the multi-platinated probe. The binding isotherm (Figure
13B) revealed that the fraction of bound probe increased to saturation over a narrow
range of hMSH2 concentrations, consistent with positive cooperative hMSH2 binding
(Hill constant nH = 2.4). The 162-bp probe used in this experiment contained an
average of six platinum adducts per duplex molecule (one platinum adduct per 27 bp).
The apparently cooperative binding behavior may thus be a consequence of multiple
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platinum adducts situated in relatively close proximity in the duplex DNA; the binding
of one hMSH2 molecule to a platinum adduct may render the subsequent binding of a
second hMSH2 molecule to a nearby platinum adduct more favorable. Alternatively,
hMSH2 may be binding as a dimer or some higher-ordered complex, as has been
previously proposed (Fishel et al., 1994a). Generation of the binding isotherm yielded
a Kd(app) = 67 nM. Neither the active fraction of the hMSH2 preparation nor the
aggregation state of the protein have been established, and thus the estimation of Kd(app)
assumes that hMSH2 binds as a monomer and that 100% of the protein is active in
cisplatin-adduct binding. These considerations, coupled with the observed complex
nature of hMSH2 binding to the multi-platinated probes, dictate that the Kd(app) be
considered only an approximation of the affinity of hMSH2 for a platinum adduct.
The specificity of the interaction between hMSH2 and cisplatin modified DNA
was examined by competing the association between hMSH2 and [32 P]-platinated DNA
with nonradiolabeled platinated or unmodified supercoiled plasmid DNA. Increasing
concentrations of unlabeled competitor DNA, either modified with cisplatin (rb =
0.043) or unmodified control, were titrated into binding reactions containing hMSH2
and radiolabeled platinated 162-bp probe (rb = 0.018). A representative experiment is
shown in Figure 14. A 400-fold molar excess of competitor platinum adducts was
required to achieve complete competition of hMSH2 binding. An approximately five-
fold greater concentration of unmodified competitor DNA compared with cisplatin
modified DNA was required to reduce binding by 50% (Figure 14b). This differential
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affinity is comparable to that observed when examining the binding of the S.
cerevisiae MSH2 protein to a G-T mismatch, four-base loop, or 14-nucleotide
palindromic insertion loop relative to homoduplex DNA (Alani et al., 1995). Previous
studies of the interaction of hMSH2 with DNA probes containing one-base mismatches
or insertion/deletion loops also found similar selectivity over homoduplex DNA (Fishel
et al., 1994a; Fishel et al., 1994b).
4. hMSH2 binds to DNA containing low levels of cisplatin modification
The degree of DNA modification by cisplatin used in the above experiments,
approximating one DNA adduct per 27 bp, is significantly higher than would be
encountered in vivo. In order to examine whether hMSH2 binds to DNA containing a
level of cisplatin modification more closely approximating that found in cellular DNA,
binding assays were carried out with hMSH2 and 162-bp probes modified to a range
of rb levels. Discrete shifted bands that represented specific binding to a cisplatin
modified DNA probe of rb = 0.018 (Figures 12, 13, 14 and Figure 15, lane 8) were
also observed when hMSH2 was included in binding reactions with DNA probes of rb
= 0.010 (Figure 15, lane 7), 0.0040 (lane 6), 0.0025 (lane 5) and 0.0012 (lane 4). The
fraction of probe bound diminished proportionately as the cisplatin modification level
decreased, reinforcing the specific nature of this shifted band. The appearance of an
increased fraction of unshifted material was likely a reflection of an increasing
population of unmodified DNA probe. The lowest modification level of rb = 0.0012
135
(lane 4) corresponded to an average of 0.4 cisplatin adducts per probe molecule. The
Poisson distribution predicts that 27% of this DNA population would contain a single
adduct, that 6% would contain two adducts, and that the remainder of the population
would be unmodified. These data thus indicated that hMSH2 is capable of binding to
DNA containing a single cisplatin adduct.
5. hMSH2 binds to the 1,2-d(GpG) intrastrand crosslink
The 1,2-intrastrand d(GpG) cisplatin crosslink represents 65% of all adducts
formed when this compound is allowed to react with DNA (Bruhn et al., 1990). The
observation that hMSH2 binds to globally modified DNA in which a maximum of one
to two cisplatin adducts were present suggested that hMSH2 may recognize this 1,2-
d(GpG) crosslink. The specificity of hMSH2 for platinum compounds that uniquely
form 1,2-intrastrand crosslinks also supported this view. Binding of hMSH2 to a 100-
bp probe containing a single d(GpG) adduct was therefore examined. Binding assays
revealed a discrete band that was specific to the platinated probe (Figure 16),
demonstrating that hMSH2 recognizes the major cisplatin crosslink. However,
nonspecific binding to the 100-bp probe was high in these gel shift assays, precluding
any thermodynamic analysis of the interaction to be carried out with confidence. The
possibility exists that the manner in which the 100 bp probe was constructed, whereby
six deoxyoligonucleotides are ligated together, contributed to the observed nonspecific
binding with this probe. Although great care was taken in purification of the
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deoxyoligonucleotides used, any failure products present could in theory lead to
internal one base extrahelical loops in the final ligated material. It is also possible that
the length of the probe contributed to this nonspecific binding by providing a high
ratio of nonspecific binding sites to specific sites. The presence of multiple cisplatin
DNA adducts, or specific binding sites, in the 162 bp DNA probe used in the
aforementioned experiments may thus have aided in the detection of specific DNA-
protein complexes over nonspecific binding. Previous binding studies with human and
yeast MSH2 have used DNA probes of approximately 35 bp in length (Alani et al.,
1995; Fishel et al., 1994a; Fishel et al., 1994b); significant nonspecific DNA binding
with the yeast protein was described (Alani et al., 1995), however, suggesting that such
binding may be characteristic of MSH2 proteins. Nevertheless, the 1,2-d(GpG) adduct
present in a shorter DNA probe for which ligation is not required could be useful in
future gel shift studies.
6. Relative expression of hMSH2 in human tissues
The expression of hMSH2 was examined by Western analysis of protein
extracts prepared from five different human tissues using hMSH2-specific monoclonal
antibody. The same amount of total protein was analyzed for each tissue examined.
A protein band of M, 105,000 was observed in all five human tissues, corresponding to
full length hMSH2 (Figure 17a). In addition, a lower band of - M, 75,000 that was of
approximately equal intensity to the full length hMSH2 band was observed in all
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tissues except the ovary, where the lower band was present but faint. This lower band
was seen both when using monoclonal antibody (Figure 17) or a polyclonal antibody
to hMSH2 (data not shown) and was not a nonspecific signal due to secondary
antibody. This protein band is believed to be a specific degradation product of
hMSH2 present in these tissue extracts. As a control, these same five human tissue
extracts were analyzed by Western analysis for a-tubulin expression (Figure 17b). A
sharp band of M, 50,000 corresponding to c-tubulin was observed. Relatively similar
levels of a-tubulin were found in all five protein extracts, demonstrating similar total
protein content for each tissue extract.
High levels of hMSH2 protein were found in both testicular and ovarian tissue,
while lower levels were observed in tissue of the liver, heart, and colon. Quantitative
analysis of hMSH2 specific signals and normalization to that of ca-tubulin for each
tissue examined indicated this enrichment of hMSH2 in testicular and ovarian tissue to
be approximately five-fold. It should be noted that five-fold is likely an underestimate
because the chemiluminescent signals due to hMSH2 in the testis and ovary lanes were
overexposed beyond the linear range of the film in order that signals could be detected
in the other tissues. The observed overexpression of hMSH2 protein in the testis is
consistent with previous results from our collaborator showing that hMSH2 is
overexpressed in human testicular tissue at the RNA level (Wilson et al., 1995).
However, elevated levels of hMSH2 RNA were not previously found in ovarian tissues
(Wilson et al., 1995), suggesting that posttranscriptional regulatory mechanisms may
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be responsible for the elevated levels found in these tissues. Tumors that arise in
tissues of the testis and ovary are those best treated by cisplatin (Loehrer and Einhorn,
1984). The correlation of the enrichment of hMSH2 in these tissues with tumor
response to cisplatin treatment supports the possibility that the protein may play a role
in sensitizing these tissues to cisplatin toxicity.
D. Discussion
1. hMSH2 binds to therapeutically active platinum DNA adducts
The work summarized in this chapter demonstrates that the human mismatch
repair protein hMSH2 recognizes and binds specifically to duplex DNA containing
cisplatin DNA adducts. The results also show that hMSH2 binds to DNA containing
adducts of the clinically effective cisplatin analog [Pt(en)C12], but not to DNA
modified with the therapeutically inactive platinum complexes trans-DDP or
[Pt(dien)Cl] +. The selective affinity of hMSH2 for DNA modified with cisplatin or
[Pt(en)C12] suggests that this protein recognizes the 1,2-intrastrand crosslinks formed
uniquely by these two compounds. Setting precedent for such specificity is HMG1,
which binds selectively to cisplatin intrastrand 1,2-d(GpG) and 1,2-d(ApG) crosslinks,
but lacks specificity for 1,3-d(GpNpG) crosslinks (Pil and Lippard, 1992). Although it
has been shown that HMG1 also binds to the interstrand crosslink of cisplatin, but not
to that formed by trans-DDP (Kasparkova and Brabec, 1995), the infrequency with
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which the cisplatin interstrand adduct is formed (2%) (Bruhn et al., 1990) suggested
that preferential recognition of this adduct in the above experiments was unlikely. An
examination of the binding of hMSH2 to a series of globally modified probes
representing a range of platinum modification levels showed that hMSH2 bound to
DNA fragments that contained a maximum of one to two cisplatin adducts; this result
supported the view that cisplatin 1,2-intrastrand crosslinks, which comprise - 90% of
the total adduct spectrum, were responsible for hMSH2 recognition. Binding assays
using a 100-bp probe containing a single, site-specific 1,2-d(GpG) crosslink (Figure
16) definitively showed that this major adduct (65%) was indeed bound by hMSH2.
Further, this result demonstrated that hMSH2 is capable of binding to a single cisplatin
DNA adduct. It should be noted that these data do not exclude the possibility that the
less abundant 1,2-d(ApG) crosslink and/or the minor interstrand crosslink may also be
recognized to some extent.
What is the basis for hMSH2 recognition of cisplatin DNA adducts? It is not
yet clear how the presence of a mismatch in the DNA helix dictates recognition by
mismatch repair proteins. In general, single-base mismatches induce very minor
distortion to the DNA helix (Werntges et al., 1986; Bhattacharyya and Lilley, 1989;
Viogt and Topal, 1990). Structural changes induced to DNA upon binding by
mismatch repair proteins have also not been described. The observation, however, that
both S. cerevisiae and human MSH2 display greater selectivity for palindromic and
loop insertion mispairs compared to single-base mismatches in vitro (Fishel et al.,
140
1994a; Alani et al., 1995) suggests that these proteins can recognize distorted DNA
structures. Bulges in DNA resulting from unpaired bases generate a directed kink in
the helical axis (Fazakerley and Boulard, 1995). The cisplatin 1,2-d(GpG) adduct
induces directed bending (340) and local unwinding (130) to the DNA helix (Bellon
and Lippard, 1990; Bellon et al., 1991), and this structural distortion dictates
recognition by HMG box proteins. Noteworthy is the structural resemblance between
insertion/deletion palindromic loops for which MSH2 proteins display greatest affinity
(Fishel et al., 1994a; Alani et al., 1995) and four-way junction and cruciform DNAs
bound by HMG proteins (Bianchi et al., 1992; Ferrari et al., 1992; Lilley, 1992). It is
thus reasonable to speculate that cisplatin adducts attract hMSH2 by distorting DNA in
a manner that mimics the presence of an insertion/deletion mispair, or a favorable
DNA structure that is formed during the assembly of mispair-protein complexes.
Further structural studies probing the nature of hMSH2-cisplatin DNA adduct
interactions are clearly warranted.
Significantly less binding was observed to DNA modified by [Pt(en)C12] than
by cisplatin (Figure 12), two compounds that form adducts at identical sites in DNA
(Eastman, 1983). This result may be explained in part by the lower level of
[Pt(en)C12] modification (rb = 0.012) compared to that of cisplatin (rb = 0.018) present
on the DNA fragments used in this experiment. Yet the observed affinities of hMSH2
for cisplatin modified DNAs of rb= 0.018 and 0.010 (Figure 15) would not predict
such a large binding differential based on the rb alone. How else might this result be
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explained? The ammine ligands of cisplatin 1,2-intrastrand adducts lie in the major
groove of DNA. Substitution of the cisplatin ammines with a series of modified
ethylenediamine derivatives does not affect binding by HMG1 (Pil, 1993), an
observation consistent with the knowledge that HMG-box proteins bind from the minor
groove side (van de Wetering and Clevers, 1992; King and Weiss, 1993; Werner et al.,
1995; Love et al., 1995). The present results could indicate that the interaction of
hMSH2 with platinum-modified DNA involves contact with the major groove.
Alternatively, the ethylenediamine ligand may modulate DNA bending and unwinding
induced by cisplatin 1,2-intrastrand adducts (Bellon and Lippard, 1990; Bellon et al.,
1991; Yang et al., 1995; Takahara et al., 1995) and interstrand crosslinks (Sip et al.,
1992; Malinge et al., 1994; Huang et al., 1995), or could restrict further bending that
may be required upon binding by hMSH2. Interestingly, in a recent study that
examined binding of mismatch repair proteins in nuclear cell extracts to DNA globally
modified with either cisplatin or the analog oxaliplatin, no binding was observed to
DNA adducts formed by the latter compound. Oxaliplatin, like [Pt(en)C12], contains a
bidentate ligand (diaminocyclohexane) in place of the two ammine groups of cisplatin,
thus reinforcing the view that such a substitution in some way interferes with hMSH2
binding (Fink et al., 1996).
2. Affinity and specificity of the hMSH2-cisplatin adduct interaction
The apparent dissociation constant for the binding of hMSH2 to a DNA
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fragment containing an average of six cisplatin adducts was found to be 67 nM. The
complex nature of binding to the multi-platinated probe in these experiments (see
Results section), however, dictates that this Kd(app) be viewed as only an approximation
of the affinity of hMSH2 for a cisplatin adduct. With this caveat in mind, the
estimated Kd(app) is roughly comparable with dissociation constants determined by
quantitative DNase I footprinting analysis for the binding of the E. coli MutS protein
to the eight possible single-base mismatches; reported Kd values range from 20 nM, for
binding to a G-T mismatch, to 480 nM, for binding to a C-C mispair (Su et al., 1988).
To date, dissociation constants for mispair-binding with either S. cerevisiae or human
MSH2 have not been described.
In this work, although binding by hMSH2 to a single, site-specific 1,2-d(GpG)
cisplatin adduct was observed, high nonspecific binding precluded thermodynamic
analysis of this interaction. It is possible that the length of the probe (100-bp) used in
the gel shift experiment, and/or the way in which the probe was constructed (see
results section), may have contributed to this nonspecific binding. However,
significant binding to homoduplex DNA has also been described for the yeast MSH2
protein (Alani et al., 1995). In general, high nonspecific binding attributed to DNA
repair proteins is not uncommon; such interactions may facilitate the linear diffusion,
or tracking, of repair proteins to specific damaged sites in the DNA. Such a model
has been suggested experimentally for the prokaryotic DNA repair enzyme T4 Endo V
(Nickell et al., 1992). With regard specifically to MSH2, it has been postulated that a
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conformation change may take place when a target site is reached that results in
increased stability of the DNA-protein complex and recognition signals for interaction
with other mismatch repair proteins (Alani et al., 1995). An examination of hMSH2
binding to the 1,2-d(GpG) cisplatin adduct present in a shorter DNA fragment may be
useful in the future towards diminishing nonspecific binding observed in this work.
The minimum DNA length required for specific hMSH2 binding has not been
examined. Footprinting studies with MutS, however, indicate that protein-DNA
contacts for the E.coli protein span approximately 20 bases surrounding the mispair
(Su et al., 1988). An examination of hMSH2 binding to cisplatin adducts by
footprinting methods may also be useful in future studies in that nonspecific binding is
less of a factor in this technique as compared with band-shift assays.
Competition studies with hMSH2 demonstrated a five-fold greater affinity for
DNA containing cisplatin adducts as compared to unmodified DNA. Previous studies
with both the S. cerevisiae and human MSH2 proteins found a similarly modest degree
of specificity for DNA containing single-base mismatches or insertion/deletion loops
over homoduplex DNA (Fishel et al., 1994a; Fishel et al., 1994b; Alani et al., 1995).
The selectivity of MSH2 proteins for DNA mispairs in vitro seems at variance with the
highly efficient repair of DNA mispairs in cells. One possible explanation may be that
productive repair is achieved through a tracking mechanism as noted above. Further
explanation, however, may have been provided by the recent discovery that hMSH2
can be purified as a heterodimer with another human MutS homolog, GTBP/p160 (also
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named hMSH6) (Palombo et al., 1995; Drummond et al., 1995). This purified
complex, termed hMutSa, also displays an affinity for DNA mispairs in vitro
(Drummond et al., 1995). Dissociation constants have not been determined, nor has
the specificity of binding been described; hence direct comparisons between binding by
hMSH2 and hMutSo can not yet be made. The most compelling evidence reported to
date for the participation of GTBP in mismatch repair comes from studies in which
tumor-derived cell lines defective in hMSH2 or GTBP were examined for mutator
phenotype, microsatellite instability (Bhattacharyya et al., 1994; Papadopoulos et al.,
1995), and for the capacity of extracts derived from these cells to carry out mismatch
repair on a series of mispaired substrates in various sequence contexts (Drummond et
al., 1995). The collective data indicate that both hMSH2 and GTBP/pl60 are required
for recognition of single- and one-base mispairs, but that recognition of larger loops,
while requiring hMSH2, can be independent of GTBP/pl60.
The observations that loop repair requires hMSH2 but not GTBP/pl60 led to
the suggestion that hMSH2, either alone or in complex with another protein,
recognizes larger loops (Papadopoulos et al., 1995; Drummond et al., 1995;
Marsischky et al., 1996). In support of the latter, two independent studies in S.
cerevisiae revealed that MSH2 forms a heterodimer not only with MSH6, the yeast
homolog of GTBP/pl60, but also with yet another MutS homolog, MSH3. Results
from these genetic studies suggested that the MSH2-MSH3 complex preferentially
recognizes insertion/deletion loops over single-base mispairs (Marsischky et al., 1996;
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Johnson et al., 1996). Supporting this view, a yeast MSH2-MSH3 heterodimer
displayed low affinity for a G/T mismatch in vitro, but bound specifically and with
increasing affinity to loops containing 2, 4, 8 and 14 extrahelical nucleotides
(Habraken et al., 1996). A recent study by Palombo et al. confirmed these results with
the human homologs; hMSH2 and hMSH3 were shown to form a heterodimer, which
they named hMutSp, and the purified complex displayed preferential affinity for loops
of two to four bases over single base mismatches and one base loops (Palombo et al.,
1996). Given that hMSH2 alone is capable of binding mispairs and insertion/deletion
loops with modest specificity, it seems that GTBP/pl60 and hMSH3 serve to modulate
hMSH2 binding specificity, and the two heterodimers hMutSa and hMutSp appear to
complement one another in mispair recognition.
While the work presented in this chapter was In Press (Mello et al., 1996), a
study of the purified heterodimer hMutSa binding to cisplatin modified DNA was
reported in the literature (Duckett et al., 1996). Results from the study complement
the work presented in this chapter. hMutSo was shown to bind tightly to the 1,2-
d(GpG) cisplatin adduct, but little or no binding was observed to the 1,3-d(GpTpG)
trans-DDP adduct. Although no dissociation constants describing the interaction were
presented, the affinity for the 1,2-d(GpG) adduct was reported to be -10-fold lower than
that for a GT mismatch, and thus comparable to the affinity of hMutSa for various
other single-base mispairs. The authors also stated that hMutSco binds poorly to the
1,2-d(ApG) and 1,3-d(GpTpG) adducts of cisplatin. Numerous experimental
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differences, including the length of the platinated DNA probe, sequence context of the
adduct, and nature of nonspecific competitor DNA in the binding reactions, make it
difficult to make any direct comparisons between binding by hMSH2 and hMutSc to
the 1,2-d(GpG) adduct. Yet it is important to note that the preferential affinity of
hMutSo for the 1,2-d(GpG) cisplatin adduct is consistent with the substrate specificity
displayed by hMSH2 in this Dissertation and in Mello et al. (1996). The reported
affinity of hMutScc for the 1,2-d(GpG) but not the 1,2-d(ApG) adduct is intriguing,
considering that the two lesions distort the DNA helix in a very similar manner
(Bellon and Lippard, 1990; Bellon et al., 1991), and suggests that a very subtle
difference in structure is detected by hMutSa. Nevertheless, the results obtained with
hMutSa strongly support the view that mismatch repair proteins may participate in the
cytotoxic response that occurs upon exposure to cisplatin. With regard to hMutSP, I
predict, based upon its preference for binding to loops over single-base mismatches,
that this complex may bind to cisplatin DNA adducts with greater affinity than hMSH2
or hMutSa. Studies addressing this question may provide insight into the basis for
recognition of cisplatin adducts by mismatch repair proteins.
3. Overexpression of hMSH2 in human testicular and ovarian tissues
Results discussed above demonstrate that hMSH2 preferentially binds to DNA
adducts of therapeutically active platinum compounds. Similar binding specificity has
been observed for HMG box proteins. To date, however, few correlations between
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expression of HMG proteins and the sensitivity of tissues to cisplatin has been found.
Expression of the HMG box protein SRY is required for testes formation, and thus
male sex determination, in the mammalian embryo (Koopman et al., 1990). Although
the expression pattern in adult tissues has not yet been carefully characterized, the
SRY transcript has indeed been detected in testicular tissue, but also in other tissues at
slightly lower levels, and SRY expression is reported to be very low overall (Cl6pet et
al., 1993). The full length SRY protein binds to the 1,2-d(GpG) cisplatin adduct with
a dissociation constant of 10-7 M and with 10-30-fold specificity over unmodified
DNA; the isolated HMG-box of SRY binds to the same lesion with 100-fold greater
affinity than the full length protein (E. Trimmer, manuscript in preparation). Thus, it
has yet to be established whether SRY may play a role in cisplatin cytotoxicity.
Although no other human HMG proteins are known to be differentially expressed in
testicular tissue, the SRY-related mouse HMG-box protein SOX5 is significantly
overexpressed in testicular tissue as compared to five other mouse tissues (Denny et
al., 1992b) and a gene encoding a human homolog has been cloned (Denny et al.,
1992a). It is also noted that a testis-specific mouse HMG-box (tsHMG) protein has
been identified (Boissonneault et al., 1993). Interestingly, a rapidly migrating subtype
of HMG2 has been observed to be present at elevated levels in testicular tissue of rat
and thirteen other vertebrate species (Bucci et al., 1985). The mRNA for hMSH2 is
overexpressed in testis (Wilson et al., 1995), a result that is extended in the present
work, which showed enhanced expression at the protein level by Western analysis.
Western analysis of hMSH2 protein in various human tissues in the present work
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indicates that hMSH2 is also present at elevated levels in ovarian tissue. These
observations are significant in that cancers occurring in testicular and ovarian tissues
are those most successfully treated by cisplatin.
Between 90 and 95% of all primary testicular malignancies are germ cell
tumors (Campbell and Walsh, 1986). In this regard it is noteworthy that the screening
of testicular germ cell tumors for microsatellite instability has revealed no
mononucleotide or dinucleotide repeat instability commonly associated with hMSH2
deficiency and colorectal cancer (Huddart et al., 1995). Approximately 20% of the
tumors showed some abnormalities, predominantly in trinucleotide and tetranucleotide
repeats, the significance of which is unknown. The results suggest that hMSH2
protein is functional in testicular germ cell tumors and thus support the notion that
mismatch repair proteins may actively contribute to the tissue-specific antitumor
activity of cisplatin.
Approximately 5 x 104 cisplatin lesions are formed in the cells of patients upon
treatment with the drug (Reed et al., 1993). Unfortunately, the relative level of
hMSH2 protein and cisplatin lesions in a cell is unknown because the number of
hMSH2 molecules in a cell has not yet been reported. It is nevertheless clear that
overexpression of this protein in specific tissues would have the effect of 1) increasing
the absolute ratio of number of molecules of hMSH2 protein to cisplatin lesions within
those cells, and 2) increasing the concentration of hMSH2 in the nucleus, where the
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protein is localized (Leach et al., 1996). With respect to the approximated dissociation
constant for the hMSH2-cisplatin adduct complex, an increase in the nuclear
concentration of hMSH2, estimated to be at least five-fold in testis and ovary as
compared to other tissues evaluated, could disproportionately increase the platinum
lesion occupancy by hMSH2. Thus, if mismatch repair proteins can in fact mediate
cisplatin lethality by any of the mechanisms discussed below, it is reasonable to predict
that they might do so most effectively in the cells of testicular and ovarian tissue.
4. Models for the participation of mismatch repair proteins in cisplatin
cytotoxicity
The results presented in this dissertation are the first demonstration that purified
hMSH2 can bind to DNA lesions other than mispaired bases or loops. This interaction
could signify the involvement of mismatch repair proteins in the removal of cisplatin
adducts from DNA. This possibility is underscored by the discovery of an association
between the genes involved in mismatch correction with transcription-coupled
nucleotide excision repair of UV damage in both E. coli (Mellon and Champe, 1996)
and eukaryotes (Mellon et al., 1996). Although the role of mismatch repair proteins in
these processes is still unclear, it is noteworthy that nucleotide excision repair is the
primary mechanism for repair of cisplatin damage and that cisplatin adducts are known
substrates for transcription-coupled repair (Jones et al., 1991; May et al., 1993). No
evidence exists, however, to suggest that the repair pathway normally responsible for
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processing of replication errors is actually involved in the repair of cisplatin damage.
Indeed, as is discussed below, the bulk of evidence available with regard to mismatch
repair and cisplatin toxicity suggests otherwise, namely that mismatch repair may
participate in the events leading to the cytotoxic response that occurs upon cellular
exposure to the drug.
The results presented in this chapter clearly demonstrate that hMSH2 displays
specificity for DNA adducts of therapeutically effective platinum complexes, results
that could imply a role for hMSH2 in mediating cisplatin toxicity. In support of this
notion, results from early work by Marinus and colleagues (Karran and Marinus, 1982;
Fram et al., 1985) demonstrate a connection between mismatch repair and cisplatin
lethality. These authors show that dam- strains of E. coli, which have decreased
adenine methylase activity and thus are unable to distinguish between parental and
newly replicated DNA strands, are hypersensitive both to the methylating agent N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG) and to cisplatin. Significantly, the
introduction of a mutation in either mutS or mutL, which inactivates mismatch repair
activity in these cells, abrogates hypersensitivity to both agents (Jones and Wagner,
1981; Karran and Marinus, 1982; Fram et al., 1985). E. coli dam- and wild type
strains are not differentially sensitive to the therapeutically inactive platinum
compound trans-DDP.
Connections between defective mismatch repair and resistance to MNNG have
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been observed in higher eukaryotes as well. Goldmacher et al. (Goldmacher et al.,
1986) isolated an MNNG-resistant derivative of the human lymphoblastoid cell line
TK6. This variant cell line exhibits a mutator phenotype and defective mismatch
repair activity in vitro (Kat et al., 1993). The observed MNNG-resistant phenotype is
not due to increased repair of 06-methylguanine (O6-MeGua), but is instead an
acquired ability to tolerate the presence of the apparently toxic methylated base in
DNA (Karran and Bignami, 1992). Independent examples of methylation-tolerant cell
lines that are defective in mismatch repair subsequently have been reported (Branch et
al., 1993; Branch et al., 1995; Aquilina et al., 1995). A model to explain this
apparently paradoxical correlation of a defect in repair with the tolerance of
methylation damage proposes a futile cycle of excision repair (Goldmacher et al.,
1986; Karran and Marinus, 1982). In this model, 06-MeGua lesions formed in DNA
are presumed to be recognized by the mismatch repair system due to the absence of a
good complementary match for the methylated base. Repair attempts at 0 6-MeGua-
containing base pairs would be directed at the newly synthesized strand after DNA
replication; failure to find a correct base pair for 0 6-MeGua would invoke a futile
cycle of incision and resynthesis in the opposing strand, resulting in the accumulation
of lethal DNA strand breaks. Tolerance results when a defect in mismatch repair
precludes initiation of this abortive repair cycle. Supporting this hypothesis is the
observation that a G-T mismatch-binding activity in cell extracts, and more recently
that the purified heterodimer hMutSac, binds efficiently to 0 6-MeGua-T base pairs in
vitro (Griffin et al., 1994; Duckett et al., 1996). Moreover, a study examining the
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processing of 0 6-MeGua in plasmid DNA by human cell extracts demonstrates that
this lesion can be processed by a pathway involving excision and resynthesis of DNA
that is not associated with the 0 6-MeGua-DNA methyltransferase enzyme (Karran et
al., 1993).
Results outlined in this chapter, viewed together with the original observations
of Marinus, suggest that a mechanism analogous to that proposed for 0 6-MeGua could
be operative in cellular processing of cisplatin adducts. By this model (depicted in
Figure 18) the mismatch recognition protein(s), at least one of which is overexpressed
in testicular and ovarian tissue, bind to cisplatin-modified bases present in the DNA.
Initial recognition triggers the recruitment of other mismatch repair proteins, including
hMLH1 and hPMS2, and the consequent initiation of misdirected repair attempts at
sites of cisplatin damage. Again, if repair were directed to the newly synthesized
strand, the cisplatin lesion responsible for recognition would be retained in the DNA,
thereby initiating a futile cycle of excision and resynthesis. This processing could
provide, perhaps through the accumulation of DNA strand breaks, a signal for
apoptosis. In this regard it is noteworthy that DNA strand breaks have been observed
in cells after treatment with cisplatin, although it is unclear whether they originated
from repair activity or as a consequence of apoptosis (Sorenson and Eastman, 1988a).
The post-replicative nature of mismatch repair suggests that this mechanism
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would be operative only for cisplatin lesions present in newly replicated DNA. It is
noteworthy that the strand signal employed for direction of long-patch mismatch repair
in mammalian cells is unknown; although the presence of nicks in DNA is capable of
both stimulating and directing mismatch repair, undirected mismatch repair does occur
in the absence of a strand interruption both in mammalian cells and cell extracts
(Varlet et al., 1996). It is therefore conceivable that mismatch repair proteins could
also attempt to process cisplatin adducts present in unreplicated DNA. It should be
noted that based on current evidence, it is possible that recognition of cisplatin adducts
by hMSH2 in complexed form with partner proteins would be required for this model
to be operative. The recent demonstration that hMutSac binds efficiently to the 1,2-
d(GpG) cisplatin adduct (Duckett et al., 1996) thus lends supports to this model.
A second and equally plausible mechanism by which hMSH2 could contribute
to the therapeutic activity of cisplatin is through the formation of a complex with
cisplatin adducts that is refractory to nucleotide excision repair (depicted in Figure 19).
It is reasoned that slow repair of cisplatin lesions would result in selective retention of
the signal that triggers cell death. This notion is supported by the observation that
XPA cells, which are deficient in nucleotide excision repair, are hypersensitive to
cisplatin (Chu and Berg, 1987). In principle, the involvement of other mismatch repair
partner proteins would not be required for this mechanism to be operative, although
the same mechanism could be proposed for the binding of hMutSa (or hMutSP3) to
cisplatin lesions. The repair shielding model has previously been proposed for the role
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of HMG proteins in cisplatin cytotoxicity. Indeed, evidence exists supporting the view
that HMG box proteins sensitize cells to cisplatin by shielding cisplatin adducts from
repair (Brown et al., 1993; Huang et al., 1994; McA'Nulty and Lippard, 1996). As
noted above, however, little correlation between the levels of HMG proteins and the
sensitivity of target tissues to cisplatin has been found. The discovery that hMSH2 is
able to bind cisplatin adducts and is also overexpressed in testicular and ovarian tissue
renders it a reasonable candidate for the repair shielding model. Further assessment of
the feasibility of this model would require knowledge of both the abundance of
hMSH2 in a cell and the true equilibrium dissociation constant for the protein-cisplatin
adduct interaction. Future experiments could be directed at determining if hMSH2,
either alone or in combination with partner proteins, shields cisplatin adducts from
repair.
An alternative to the above models is that the recognition of cisplatin DNA
adducts by hMSH2 could induce cell death by interface with cellular processes other
than mismatch repair (depicted in Figure 20). The recognition by mismatch repair
proteins of other types of DNA damage, including UV dimers (R. Fishel, unpublished
data), DNA adducts formed by 2-aminofluorene and N-acetyl-2-aminofluorene (Li et
al., 1996), and base pairs involving 06-MeGua and 04 -methylthymine (O4-MeT)
(Duckett et al., 1996), has led to the suggestion that mismatch repair proteins may
serve as general sensors of genetic damage (Kat et al., 1993; Koi et al., 1994). Of
relevance is the recent observation that the mismatch repair deficient, alkylation
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tolerant cell line HCT116, which is deficient in hMLH1, fails to arrest at the G2
checkpoint upon exposure to the base analog 6-thioguanine (Hawn et al., 1995).
Similar behavior is seen with a cell line deficient in GTBP/pl60 following treatment
with MNNG (Goldmacher et al., 1986). It is proposed that the mismatch repair system
may be involved in triggering G2 arrest in response to alkylating agents, either through
the generation of DNA strand breaks, or by interacting directly or indirectly with other
protein(s) responsible for the G2 checkpoint (Hawn et al., 1995). It is well established
that cisplatin treatment of mammalian cells causes an arrest at G2 for several days,
after which cells either recover or become apoptotic (Sorenson and Eastman, 1988a;
Sorenson and Eastman, 1988b; Sorenson et al., 1990; Piacentini et al., 1993; Evans
and Dive, 1993; Shinomiya et al., 1994). Thus hMSH2 recognition may be involved
in cisplatin-induced cell death through the provision of a signal for G2 arrest that does
not involve an excision activity associated with mismatch repair. Preliminary
experiments carried out by M. Kartalou in our laboratory indicate that the mismatch
repair deficient cell line LoVo, which is defective in hMSH2, fails to arrest at G2 after
treatment with cisplatin, suggesting that this phenomenon may not be limited to
alkylating agent damage.
The models outlined above could conceivably operate in concert to aid the
organotropic cytotoxicity of cisplatin. One possible complication is the possibility that
HMG box proteins, which are abundant in the cell, may interfere with the ability of
hMSH2 to gain access to the cisplatin adducts. Of primary concern in this regard is
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hUBF, an HMG protein that binds to cisplatin adducts three to four orders of
magnitude more tightly than other known HMG proteins (Treiber et al., 1994). It is
noted, however, that hUBF is localized in the nucleolus (Roussel et al., 1993) whereas
hMSH2 appears to be more generally distributed in the nucleus (Leach et al., 1996).
It is not anticipated, therefore, that hUBF would necessarily compete with hMSH2 for
cisplatin adducts in nuclear DNA. By contrast, HMG1, which is not localized to the
nucleolus, is approximately ten-fold more abundant than hUBF and binds to the
cisplatin 1,2-d(GpG) and -d(ApG) adducts with a Kd(app) = 370 nM (Pil and Lippard,
1992). Further speculation on this issue is difficult, however, as neither the abundance
of hMSH2 in a cell nor the true binding constant for the interaction of hMSH2 (or
hMutSc) with a cisplatin adduct is known at this time.
5. Evidence in vivo for a connection between human mismatch repair proteins
and cisplatin cytotoxicity
A growing body of work exists implicating mismatch repair machinery as a
modulator of the cytotoxic response of mammalian cells to cisplatin. The first line of
evidence comes from the analysis of cisplatin resistant human cell lines. A panel of
tumor cell lines selected for resistance to cisplatin following exposure to the drug were
screened for the RER' phenotype that is associated with defects in mismatch repair.
This phenotype was found to be common in the cisplatin resistant lines, and one such
RER+ cell line was examined and shown to be deficient in G-T mismatch binding
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activity (Anthoney et al., 1996). In independent studies, other tumor cell lines selected
for resistance to cisplatin were found to display a mutator phenotype, microsatellite
instability (Aebi et al., 1996), and to contain associated defects in the mismatch repair
proteins hMLH1 and hPMS2 (Aebi et al., 1996; Drummond et al., 1996). It is
noteworthy that while these studies show that loss in mismatch repair can accompany
cisplatin resistance, they do not in any way indicate that such repair deficiency is
actively contributing to that resistance.
Complementary studies to those described above have attempted to determine
whether loss of mismatch repair in itself can contribute to cisplatin resistance. Studies
show that the mismatch repair deficient cell lines HCT116 and HEC59, which are
defective in hMLH1 and hMSH2, respectively, are two fold resistant to cisplatin when
compared to proficient sublines complemented with the chromosome carrying the
respective functional gene2 (Aebi et al., 1996; Fink et al., 1996). Similar differential
sensitivity was also observed to the therapeutically effective cisplatin analog
carboplatin (Fink et al., 1996). By contrast, these mismatch repair deficient and
proficient cell lines are not differentially sensitive to trans-DDP or several other
platinum complexes, including oxaliplatin (Fink et al., 1996). In this same study, gel
mobility shift assays carried out with nuclear cell extracts demonstrate that, in contrast
to cisplatin modified DNA, DNA modified by oxaliplatin was not recognized by
2 The HCT116 cell line may harbor an additional defect in hMSH3 (R. Fishel,
personal communication).
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mismatch repair proteins present in the extracts. These results support the view that
recognition of platinum DNA adducts by mismatch repair proteins has a functional
consequence, namely a change in drug sensitivity. Studies carried out by M. Kartalou
in our laboratory have also found that mismatch repair deficient cells are two to four
fold resistant to cisplatin compared to normal cells. The cell lines used in the latter
work are not isogenic, however, and hence the observed resistance cannot be
definitively attributed to mismatch repair. Studies on isogenic cell lines are in
progress.
The results detailed above could have far-reaching implications for the problem
of acquired clinical resistance to cisplatin. A tumor that acquires resistance to cisplatin
and an associated loss in mismatch repair following treatment with the drug would
likely display cross-resistance to methylating, and perhaps other alkylating (e.g., N,N'-
bis(2-chloroethyl)-N-nitrosourea (Tong et al., 1982)) anticancer agents. Likewise, the
inactivation of the mismatch repair pathway by alkylating agent anticancer drugs may
lead to tumors that are relatively refractory to treatment by cisplatin. Such
observations may have profound clinical importance in determining optimum treatment
regimens for cancer patients. Moreover, a further understanding of the precise role
mismatch repair proteins may play in the therapeutic mechanism of cisplatin may
ultimately prove useful in the design of more effective anticancer drugs.
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E. Conclusions and Future Experiments
The work summarized in this chapter demonstrates a novel platinum adduct
binding property of the human mismatch repair protein, hMSH2. The protein binds
selectively to the adducts of platinum based drugs that show clinical efficacy or
potential. The significance of the work is threefold. First, hMSH2 is overly expressed
in testis and ovary, the two tissues in which tumors are best treated by cisplatin.
These observations suggest that hMSH2 may contribute to the organotropism of the
drug. Second, the present demonstration of an interaction between hMSH2 and
cisplatin DNA adducts in vitro complements a growing body of literature correlating
mismatch repair activity with both cisplatin and methylating agent cytotoxicity.
Viewed together, these observations are consistent with a model whereby mismatch
repair plays an active role enhancing DNA lesion toxicity. Moreover, because
mismatch repair deficiency correlates with resistance to alkylating agents, our results
may provide insight into a heretofore undiscovered mechanism by which tumor cells
may acquire resistance to cisplatin. Finally, the demonstration that hMSH2 binds to
DNA lesions other than single-base mismatches and insertion/deletion mispairs could
imply a broader range of substrates for the mismatch repair system, and the possibility
of multiple roles for mismatch recognition proteins. Based on the results of this
dissertation, the following are suggested for future studies.
1. Both hMSH2 and GTBP/p160 together are presently believed to function as a
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recognition complex in mismatch repair. Yet hMSH2 alone is capable of binding to
mispairs and DNA damage in vitro. It thus remains unclear whether such recognition
by hMSH2 alone occurs in vivo, and whether such binding may be productive. A
direct comparison of the binding by hMSH2 and the heterodimer hMutSoa to a
cisplatin lesion, involving both thermodynamic and kinetic analysis, would provide
biochemical evidence for which protein(s) are most likely to interact with cisplatin
adducts in vivo. Information gained from these experiments could reveal the nature of
the individual contributions made by GTBP/pl60 to the formation of hMutSa-DNA
mispair complexes.
2. As was discussed above, hMSH2 forms complexes with both GTBP/pl60 and
hMSH3 to form hMutSa and hMutSP, respectively. These two heterodimers display
complementary binding specificities, whereby hMutSa binds preferentially to single
base and one base mispairs and hMutSP shows greatest affinity for two base or larger
insertion/deletion loops. The DNA bending and unwinding induced by cisplatin DNA
adducts would suggest that hMutSP, which binds preferentially to the subset of
mispairs that create the greatest distortion to DNA, might also recognize cisplatin
lesions. A comparison by gel shift assay of the binding of hMutSa and hMutSP to the
1,2-d(GpG) adduct should be carried out to address this question. The relative binding
of the two recognition complexes to the 1,2-d(ApG), 1,3-d(GpNpG) and to the
interstrand crosslink would also be interesting to examine. Results of these studies
would provide insight into the basis for recognition of both mispaired substrates and
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cisplatin adducts by these mismatch recognition proteins. Further, they could indicate
which heteroduplex would be most likely to play a role in the processing of cisplatin
adducts by mismatch repair in vivo.
3. The structural features of DNA-protein complexes formed by hMSH2, hMutSCa or
hMutSP are completely unknown. An examination of mismatch recognition protein(s)
binding to DNA that is modified with platinum compounds in which the cisplatin
ammines are substituted with various bulky ethylenediamine derivatives could provide
information as to whether minor groove contacts are important for binding. More
direct information, however, could be obtained through both DNase I footprinting and
methylation protection footprinting analysis, and eventually by NMR and X-ray
crystallography. Such studies could provide information regarding: 1) the extent of
protein-DNA contacts surrounding the mispair or cisplatin adduct, 2) whether the
mismatch repair protein(s) make primarily major or minor groove contacts, and 3)
whether GTBP/pl60 or hMSH3 modulates hMSH2 binding specificity through the
provision of additional DNA contacts.
4. Initial cisplatin cytotoxicity assays have been carried out by M. Kartalou in the
laboratory using a panel of mismatch repair deficient and proficient, but non-isogenic,
cell lines; although results indicate a 2-4 fold resistance to cisplatin of mismatch repair
deficient cells compared to proficient cells, definitive conclusions cannot be made
owing to the different genetic backgrounds of the cells. Cytotoxicity assays should
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ideally be carried out with a panel of isogenic cell lines in which each of the mismatch
repair recognition proteins, hMSH2, GTBP/pl60, and hMSH3 are defective. These
studies will complement the binding experiments involving hMutSa and hMutSP
proposed above. The relative binding affinities of hMutSC and hMutSP3 for cisplatin
adducts would perhaps be reflected in the cisplatin sensitivities of cell lines defective
for the corresponding proteins. For example, if hMutSP were found to bind
significantly more tightly to cisplatin adducts than hMutSO, then it would be predicted
that cell lines deficient in hMSH3 or hMSH2 would be more resistant to cisplatin
toxicity than cell lines deficient in GTBP/pl60. Examination of isogenic cell lines
deficient in other proteins required for repair, including hMLH1 and hPMS2, would
indicate whether subsequent binding of these proteins to the initial recognition complex
is required for the putative processing of cisplatin adducts by mismatch repair.
Isogenic cell lines created in Hein te Riele's laboratory in the Netherlands will enable
this work.
5. In conjunction with the toxicity assays described above, the possible role of
mismatch recognition proteins in the G2 checkpoint in response to cisplatin treatment
could also be addressed. Following treatment of mismatch repair proficient and
deficient cell lines with cisplatin, the population of cells in each phase of the cell cycle
can be examined by using flow cytometry. As noted in the discussion, preliminary
experiments carried out by M. Kartalou in our laboratory indicate that the hMSH2
deficient cell line LoVo lacks the ability to arrest at G2 upon cisplatin treatment, but
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that other cell lines deficient in hMLH1 or GTBP/pl60 do not exhibit this same defect.
As the cell lines used in this experiment are not isogenic, and controls with
methylating agents have not yet been carried out, the potential role of mismatch repair
in cisplatin induced G2 arrest is still unclear. The panel of isogenic cell lines
discussed above will thus also prove useful in these studies.
6. A DNA repair synthesis assay using replication competent cell-free extracts has
previously been used to demonstrate that 0 6-MeGua lesions are processed in vitro by a
pathway that involves the excision and T-antigen independent resynthesis of DNA; the
demonstration that such processing is absent in extracts made from mismatch repair
deficient cells attributes these activities to the mismatch repair machinery (Karran et
al., 1993; Ceccotti et al., 1996). The proposed abortive repair mechanism for cisplatin
adducts could thus be tested in vitro by examining whether excision and DNA
synthesis activity due to mismatch repair is provoked by cisplatin modified DNA by
using this same system. A key feature of this assay is that nucleotide excision repair
is apparently not active in the cytoplasmic cell extracts used, thus eliminating the
significant potential problem of simultaneous cisplatin adduct repair by the nucleotide
excision repair machinery. It is possible that globally modified plasmid DNA could be
useful for such studies, although plasmids containing single site-specific cisplatin
adducts would be the ideal substrates. The preparation of such substrates has been a
longstanding area of expertise in this laboratory.
164
7. The proposed repair shielding model could be tested in vitro by using either
purified UvrABC proteins or mammalian cell extracts competent for repair.
Preincubation of DNA substrates containing either global or site-specific DNA damage
with mismatch recognition protein(s) facilitates formation of DNA-protein complexes.
DNA substrates are then added to repair reactions and the effect of bound protein(s) on
the repair of platinum adducts is monitored. With regard specifically to the 1,2-
d(GpG) adduct, excision repair of this lesion was previously found to be inefficient in
assays using mammalian cell extracts; the methods of J. Huang et al. (Huang et al.,
1994) have subsequently allowed detection of such repair in vitro and may therefore be
useful in such studies.
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Figure 10: Southwestern and Western analysis of HeLa and N-Tera 2.D1 cell extracts.
Parallel blots of HeLa whole cell extract (HWC), HeLa nuclear extract (HN), and N-
Tera 2.D1 whole cell extract (NTer) were probed with radiolabeled cisplatin modified
DNA in Southwestern analysis (A) or monoclonal antibody for hMSH2 in Western
analysis (B). In Southwestern analysis, control blots of HWC and HN were probed
with radiolabeled unmodified DNA or DNA modified with trans-DDP (A). The
molecular weights of species detected in HeLa cell extract that recognize cisplatin
modified DNA are noted in A. The position of hMSH2 is shown in the Western blot
(B).
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Figure 11: Structures of platinum compounds used in hMSH2 binding studies.
Cisplatin (cis-DDP) and [Pt(en)C12], both therapeutically active platinum complexes,
have chloride ligands in the cis geometry. The trans isomer of cisplatin, trans-DDP,
and [Pt(dien)Cl]Cl are clinically ineffective cisplatin analogs.
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Figure 12: Selectivity of hMSH2 for DNA modified with therapeutically active
platinum compounds. Radiolabeled 162-bp DNA probe was modified with cisplatin
(lanes 3 and 4), trans-DDP (lanes 5 and 6), [Pt(en)C12] (lanes 7 and 8), or
[Pt(dien)Cl]Cl (lanes 9 and 10) at drug-to-nucleotide ratios (rb) = 0.018, 0.036, 0.012,
and 0.020, respectively. Unmodified 162-bp probe appears in lanes 1 and 2. DNA
probes were incubated in the absence (-) or presence (+) of hMSH2 (100 nM). Two
discrete shifted bands were observed only when hMSH2 was incubated with DNA
containing adducts of the therapeutically active complexes cisplatin or [Pt(en)C1l2
(lanes 4 and 8, respectively).
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Figure 13: Binding isotherm describing the interaction between hMSH2 and cisplatin-
modified DNA. (A) hMSH2 protein was titrated into binding reactions containing 124
pM radiolabeled 162-bp probe that contained an average of 6 cisplatin DNA adducts
(rb = 0.018). Cisplatin-modified probe in the absence of hMSH2 is shown in lane 1.
(B) The fraction of bound probe in each lane was quantitated by PhosphorImager
analysis and is presented as a function of the concentration of hMSH2 present in the
binding reactions. The binding curve was generated by fitting these binding data to
the Hill equation.
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Figure 14: Specificity of hMSH2 binding to cisplatin-modified DNA. Unlabeled
duplex DNA, either cisplatin-modified or unmodified control, was used to compete the
association between hMSH2 and a radiolabeled 162-bp cisplatin-modified DNA probe.
(A) 32P-labeled 162-bp probe modified with cisplatin (rb = 0.018, 150 pM) was
incubated in the presence of hMSH2 (100 nM) and 0-710 pM unlabeled cisplatin-
modified DNA (rb = 0.043) (left panel), or 0-6400 pM unlabeled unmodified DNA
(right panel). Cisplatin-modified probe in the absence of hMSH2 is shown in lane 1
for either competitor. (B) The fraction of bound probe in each lane was quantitated by
Phosphorlmager analysis and is presented as a function of the concentration of
competitor DNA present in the binding reactions.
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Figure 15: Binding of hMSH2 to cisplatin-modified DNA at different bound ratios of
Pt/nucleotide (rb). Radiolabeled 162-bp probe modified with cisplatin at drug-to-
nucleotide ratios of 0.0012 (lane 4), 0.0025 (lane 5), 0.0040 (lane 6), 0.010 (lane 3
and 7) and 0.018 (lane 8), corresponding to an average of 0.4, 0.8, 1.3, 3.4 and 6
cisplatin adducts per probe molecule, respectively, were incubated in the absence (-) or
presence (+) of hMSH2 (130 nM). Unmodified probe appears in lanes 1 and 2.
Retarded bands representing specific binding of hMSH2 to the DNA probe of rb
0.018 (Figures 12, 13 and 14 and Figure 15, lane 8) were also present at the lower
levels of platinum modification. Specific binding diminished as the degree of cisplatin
modification decreased. The broad, faster migrating band present in all lanes
containing protein represents nonspecific binding to the 162-bp probe that was
incompletely competed by nonspecific competitor DNA present in the binding
reactions.
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Figure 16: Binding of hMSH2 to a 100-bp probe containing a single, site-specific 1,2-
d(GpG) cisplatin intrastrand crosslink. hMSH2 (160 nM) was incubated with 100-bp
probe that contained the major cisplatin adduct or with its unplatinated control (100
pM). A discrete shifted band was visible that was specific for the platinated probe,
while a faster migrating band representing nonspecific binding was observed with both
the platinated and unplatinated probes.
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Figure 17: Western blot analysis of hMSH2 expression in human tissue. (A) Protein
extracts derived from human tissues were electrophoresed on SDS-polyacrylamide gels,
transferred to nitrocellulose, and probed with monoclonal antibody to hMSH2.
Nuclear extract of HeLa cells and purified hMSH2 were included as positive controls.
Lane 1, Heart; Lane 2, Liver; Lane 3, Ovary; Lane 4, Testis; Lane 5, Colon; Lane
6, HeLa nuclear extract; Lane 7, purified hMSH2 from a separate loading. The upper
band corresponds to full length hMSH2 protein, Mr 105,000. The lower band is
believed to be a specific degradation product of hMSH2 present in these tissue
extracts. (B) Protein extracts from human tissues were blotted and probed with
monoclonal antibody to ca-tubulin, demonstrating similar total protein content for each
tissue sample.
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Figure 18: The abortive repair model for the role of hMSH2 in potentiating cisplatin
cytotoxicity. See text (discussion section) for details.
182
5'1C~isnk~tin Adducrt
hMSH3
GTBP/pl60 L -G
3'
C
-G
hMLH1
hPMS2
Al/7
Recognition
(Accumulation
of Strand Breaks)
Ii
Incision *-G
Abortive
Repair
rvl•eIA
E
Excision
I¼ /
Resynthesis
I T
i
I -0 -GI
I
1
I .
I
Figure 19: The repair shielding model for the participation of hMSH2 in mediating
cisplatin cytotoxicity. See text (discussion section) for details.
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Figure 20: A model describing a role for hMSH2 in cisplatin toxicity in which
hMSH2 acts as a general sensor of genetic damage and provides a signal resulting in
arrest at the G2 cell-cycle checkpoint. See text (discussion section) for details.
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